Type 1 Diabetes Mellitus

On this page

Quick Reference

RxDrug of choiceInsulin degludec (basal) 0.2-0.4 U/kg once daily plus insulin aspart (prandial) 0.05-0.15 U/kg per meal

AltAlternativesInsulin glargine U100 0.2-0.4 U/kg once daily; insulin lispro or glulisine for prandial coverage; insulin pump (CSII) with rapid-acting analogue; advanced hybrid closed-loop (AHCL) system

⊘AvoidSGLT2 inhibitors (dapagliflozin, empagliflozin) outside clinical trials due to DKA risk; non-dihydropyridine CCBs (diltiazem, verapamil); NPH insulin as first-line if analogue available (higher nocturnal hypoglycemia)

DxTest of choiceC-peptide (fasting <0.2 nmol/L or stimulated <0.6 nmol/L) plus islet autoantibody panel (GADA, IA-2A, ZnT8A) to confirm autoimmune T1DM

ScKey scoreADA staging: Stage 1 (≥2 autoantibodies, normoglycemia), Stage 2 (autoantibodies + dysglycemia), Stage 3 (clinical diabetes); HbA1c target <7.0%

→When to referDKA with pH <7.0 or altered mental status (ICU); recurrent severe hypoglycemia despite optimized therapy (consider pancreas/islet transplant); pregnancy for preconception counseling; antibody-negative diabetes with suspected monogenic cause (genetic testing)

T1DM requires lifelong basal-bolus insulin replacement titrated to HbA1c <7.0% with CGM to maximize time-in-range and minimize hypoglycemia; DKA management follows a protocol of fluid resuscitation, IV insulin, and potassium replacement without routine bicarbonate.

Type 1 diabetes mellitus (T1DM) is a chronic autoimmune endocrine disorder characterized by absolute insulin deficiency from progressive pancreatic beta-cell destruction. It accounts for 5-10% of all diabetes, most common in children and adolescents. Acute complications include diabetic ketoacidosis (DKA) and severe hypoglycemia; chronic complications include retinopathy, nephropathy, neuropathy, and accelerated cardiovascular disease. Early recognition and intensive insulin therapy are critical to reduce morbidity and mortality.

Overview and Recommendations

Background

•Type 1 diabetes mellitus (T1DM), absolute insulin deficiency from autoimmune beta-cell destruction, affects approximately 1.45 million people in the United States, with a global incidence rising 3-4% per year, a pace too rapid for genetic drift alone.
•The disease follows a predictable staging paradigm: Stage 1 (≥2 islet autoantibodies, normoglycemia), Stage 2 (autoantibodies plus dysglycemia), and Stage 3 (symptomatic hyperglycemia). Progression from Stage 1 to clinical diabetes occurs in >70% of individuals over 5 years.
•The autoimmune attack targets well-characterized beta-cell antigens: GAD65 (glutamic acid decarboxylase), IA-2 (insulinoma-associated protein 2), ZnT8 (zinc transporter 8), and insulin. CD8+ cytotoxic T-cells mediate destruction via perforin/granzyme and Fas-FasL pathways.
•Genetic susceptibility is dominated by HLA class II haplotypes DR3-DQ2 and DR4-DQ8 (OR >20 for heterozygotes), with additional risk from non-HLA loci including PTPN22, INS, CTLA4, and IL2RA. Environmental triggers, most consistently enteroviral infection, initiate or accelerate autoimmunity in genetically predisposed individuals.

Evaluation

•Suspect T1DM in any patient with polyuria, polydipsia, unintentional weight loss (5-10% over weeks), fatigue, blurred vision, or new-onset nocturnal enuresis in children.
•Ask about the duration of symptoms, classic T1DM progresses over 2-6 weeks in children and adolescents; adults may have a more insidious course over months.
•Ask about family history of T1DM (RR 15 for first-degree relatives), other autoimmune diseases (thyroid, celiac, Addison's), and recent viral illness.
•Examine for signs of dehydration (dry mucous membranes, reduced skin turgor, tachycardia), Kussmaul respirations, acetone breath, and altered mental status indicating DKA.
•Order STAT fingerstick blood glucose and urine or serum ketones (beta-hydroxybutyrate) in any symptomatic patient.
•Confirm diabetes with fasting glucose ≥126 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%.
•Assess for DKA using the triad: glucose >250 mg/dL, venous pH <7.3, serum bicarbonate <15 mEq/L, and positive ketones.
•Measure C-peptide (fasting or stimulated) to distinguish T1DM from type 2 diabetes: fasting C-peptide <0.2 nmol/L (<0.6 ng/mL) confirms absolute insulin deficiency.
•Order islet autoantibody panel (GADA, IA-2A, ZnT8A), ≥1 positive confirms autoimmune etiology; panel sensitivity is 85-90% at diagnosis.
•If autoantibodies are negative, consider genetic testing for monogenic diabetes (WFS1, INS, GCK, HNF1A, HNF4A), especially in young children or those with family history.
•Screen for associated autoimmune diseases at diagnosis: TSH and TPO antibodies (autoimmune thyroid disease in 15-30% of T1DM), tissue transglutaminase IgA (tTG-IgA) for celiac disease.
•In a patient with DKA, assess severity by venous pH (mild pH 7.25-7.30, moderate pH 7.00-7.24, severe pH <7.00) and triage to appropriate level of care.
•Use an algorithm for antibody-negative cases: if C-peptide low, consider idiopathic T1DM or monogenic diabetes; if C-peptide normal/high, consider type 2 diabetes or MODY.

Management

•Initiate insulin therapy immediately once T1DM is confirmed. Start basal-bolus regimen at total daily dose (TDD) of 0.5-1.0 U/kg/day.
•Administer 50% of TDD as basal insulin, insulin degludec (0.2-0.4 U/kg once daily), glargine U100 (0.2-0.4 U/kg once daily), or glargine U300 (0.3-0.5 U/kg once daily). Degludec reduces nocturnal hypoglycemia vs glargine (rate ratio 0.75, 95% CI 0.59-0.96).
•Administer 50% of TDD as prandial rapid-acting analogue (lispro, aspart, glulisine) at 0.05-0.15 U/kg per meal, adjusted for carbohydrate content and premeal glucose.
•For DKA: fluid resuscitation with 0.9% normal saline 15-20 mL/kg over first hour (1 L in adults), then 250-500 mL/h. Replace half the deficit over 8 hours.
•For DKA: after fluids, give regular insulin 0.1 U/kg IV bolus, then 0.1 U/kg/h continuous IV infusion. Do not start insulin if K+ <3.3 mEq/L, replete potassium first.
•When blood glucose falls to 250 mg/dL, add 5% dextrose to IV fluids and reduce insulin to 0.05-0.1 U/kg/h to maintain glucose 150-200 mg/dL until acidosis resolves.
•Replace potassium when serum K+ <5.3 mEq/L: add 20-30 mEq potassium chloride or phosphate per liter IV fluid, target K+ 4-5 mEq/L. Monitor every 2 hours.
•Reserve bicarbonate for pH <6.9: give 50-100 mEq NaHCO₃ in 200 mL sterile water over 30-60 minutes with ECG monitoring. Do not use routinely.
•Transition from IV to subcutaneous insulin only after DKA resolves (anion gap <12 mEq/L, pH >7.3). Overlap IV and SC insulin by 1-2 hours.
•Titrate all patients to HbA1c <7.0% (<53 mmol/mol) for most nonpregnant adults; target <7.5% for children and adolescents to balance hypoglycemia risk.
•Prescribe continuous glucose monitoring (CGM) for all patients with T1DM, reduces severe hypoglycemia by 40-50% and improves HbA1c by 0.3-0.5% in adults ≥25 years.
•Advanced hybrid closed-loop systems (MiniMed 780G, Tandem Control-IQ) are recommended as preferred therapy, achieve time-in-range >70% with reduced hypoglycemia.
•For severe hypoglycemia (unconscious or unable to swallow): give glucagon 1 mg IM or intranasal 3 mg, or IV dextrose 50% 25 g. Recheck in 15 minutes.
•For conscious hypoglycemia (<70 mg/dL): administer 15-20 g oral glucose (4 oz juice, 3-4 glucose tablets); repeat in 15 minutes if still <70 mg/dL.
•Anticoagulate with statins in all patients aged ≥40 years, or younger with LDL ≥100 mg/dL, hypertension, smoking, or family history of premature CVD. Target LDL <70 mg/dL.
•Add ACE inhibitor or ARB when urinary albumin-to-creatinine ratio (UACR) >30 mg/g, regardless of blood pressure, to slow nephropathy progression.
•Do not use SGLT2 inhibitors as routine adjunct, 3.5-fold increased DKA risk (NNH = 28) and FDA boxed warning; consider only in clinical trials.
•Do not use non-dihydropyridine CCBs (diltiazem, verapamil), they exacerbate heart failure in diabetic cardiomyopathy.
•Do not omit basal insulin during illness or fasting, this is the most common precipitant of DKA. Increase insulin by 20-50% during intercurrent illness.

Board Review — High Yield

•DCCT/EDIC study, intensive insulin therapy (HbA1c ~7%) reduces retinopathy by 76%, nephropathy by 54%, CVD by 42%; legacy effect persists for decades despite later HbA1c convergence.
•C-peptide <0.2 nmol/L, distinguishes T1DM (absolute deficiency) from T2DM with high specificity; stimulated C-peptide <0.6 nmol/L confirms severe beta-cell loss.
•GADA, IA-2A, ZnT8A, ≥1 positive confirms autoimmune etiology; ZnT8A useful in antibody-negative cases and may signal concurrent autoimmune thyroiditis.
•HLA DR3-DQ2 and DR4-DQ8, strongest genetic risk (OR >20 for heterozygotes); non-HLA loci (PTPN22, INS, CTLA4) contribute modest additive risk.
•DKA triad, glucose >250 mg/dL, pH <7.3, bicarbonate <15 mEq/L with ketones; treatment: NS 15-20 mL/kg, IV insulin 0.1 U/kg bolus + 0.1 U/kg/h, K+ replacement.
•DO NOT use bicarbonate for DKA unless pH <6.9, no outcome benefit, may worsen hypokalemia and cerebral edema.
•Advanced hybrid closed-loop (AHCL), preferred therapy; MiniMed 780G and Tandem Control-IQ achieve TIR >70% with fewer hypoglycemic events vs MDI.
•SGLT2i contraindicated in T1DM, 3.5-fold DKA risk (NNH 28); avoid outside clinical trials despite HbA1c reduction of 0.37%.
•Autoimmune polyglandular syndrome type 2, Addison disease + T1DM or thyroid disease; screen with TSH, TPO antibodies, tTG-IgA at diagnosis; annual TSH thereafter.
•Teplizumab (anti-CD3), first FDA-approved disease-modifying therapy; delays progression from Stage 2 to Stage 3 T1DM by ~2 years in at-risk individuals.

Deep Dive — Evidence Details

Definition, Classification and Axis Nomenclature

▸T1DM is absolute insulin deficiency from autoimmune beta-cell destruction; variants include classic, LADA, fulminant, and ICI-induced.
▸Staging: Stage 1 (autoantibodies, normoglycemia) to Stage 3 (symptomatic hyperglycemia); honeymoon phase is transient partial remission.

HY High Yield: LADA (GAD65 antibody testing) prevents misclassification as type 2 diabetes and delays insulin initiation [3,7].

Type 1 diabetes mellitus (T1DM) is a chronic autoimmune endocrine disorder characterized by absolute insulin deficiency from progressive destruction of pancreatic beta cells. Synonyms include type 1 diabetes (T1D), insulin-dependent diabetes mellitus (IDDM), juvenile-onset diabetes (historical), autoimmune diabetes, latent autoimmune diabetes in adults (LADA) ^[3]^B3b, and slowly progressive insulin-dependent diabetes mellitus (SPIDDM) ^[3]^B3b. Variants: classic T1DM (childhood-onset, acute DKA, high-titer autoantibodies), LADA (adult-onset >30 years, initial non-insulin requirement, GAD65 antibodies) ^[3]^B3b, fulminant T1DM (abrupt onset, rapid beta-cell destruction, often no autoantibodies, East Asian populations), and immune checkpoint inhibitor-induced T1DM (iatrogenic, anti-PD-1/PD-L1 therapy, rapid onset with DKA) ^[13]^C4. Staging: Stage 1 (presymptomatic, ≥2 islet autoantibodies, normoglycemia), Stage 2 (presymptomatic with dysglycemia), Stage 3 (symptomatic hyperglycemia, often DKA) ^[4]^B2c. Honeymoon phase: transient partial remission after insulin initiation. T1DM accounts for 5-10% of all diabetes; DKA 30-day readmission rate 18.7% ^[4]^B2c; retinopathy prevalence 6.7% ^[8]^A1a; waist-to-height ratio ≥0.6 increases cardiovascular risk HR 1.72 ^[10]^B2b. Associated autoimmune conditions: celiac disease, polycystic ovary syndrome ^[5]^B3b^[6]^B3b. Pearl: Type 1 diabetes is defined by absolute insulin deficiency from autoimmune beta-cell destruction, classified into classic, LADA, fulminant, and ICI-induced variants, and staged from presymptomatic autoimmunity to symptomatic hyperglycemia; early recognition of LADA (GAD65 antibody testing) can prevent misclassification as type 2 diabetes and delay insulin initiation ^[3]^B3b^[7]^D5.

Classification of Type 1 Diabetes Variants

Variant	Key Distinguishing Feature	Associated Marker/Subtype
Classic T1DM (childhood-onset)	Acute presentation with DKA; rapid beta-cell loss	High-titer GAD65, IA-2, ZnT8 autoantibodies; HLA-DR3/DR4
Latent autoimmune diabetes in adults (LADA)	Adult-onset (>30 years); initial non-insulin requirement for months to years	GAD65 autoantibodies; slower decline in C-peptide ^[3]^B3b
Fulminant T1DM	Abrupt onset with extremely rapid beta-cell destruction; often no autoantibodies	Idiopathic; associated with HLA-DR4-DQ4; common in East Asian populations
Immune checkpoint inhibitor-induced T1DM	Iatrogenic; triggered by anti-PD-1/PD-L1 therapy	Rapid onset; often with DKA; may have low or absent autoantibodies ^[13]^C4

Axis Physiology, Pathophysiology and Biochemical Signature

▸Autoimmune destruction targets GAD65, IA-2, ZnT8, insulin; autoantibodies are biomarkers.
▸Biochemical signature: hyperglycemia + low C-peptide + ketosis + positive autoantibodies.

HY High Yield: C-peptide <0.2 nmol/L fasting confirms absolute insulin deficiency; stimulated C-peptide <0.6 nmol/L after mixed-meal is gold standard for residual function.

Normal glucose homeostasis: beta-cells sense glucose, secrete insulin in biphasic pattern (first-phase burst, then sustained second-phase). Incretins (GLP-1, GIP) amplify secretion. Insulin suppresses glucagon. Failure: autoreactive T-cells infiltrate islets (insulitis), targeting autoantigens: insulin, GAD65, IA-2, ZnT8 ^[7]^D5. Autoantibodies are biomarkers, not pathogenic. Stepwise destruction: 1) Genetic predisposition (HLA-DR3-DQ2, DR4-DQ8; non-HLA: PTPN22, INS, CTLA4, PTPN2) ^[36]^B3b^[46]^D5. 2) Environmental trigger (viral infection, e.g., enterovirus, HCMV, rotavirus) via TLR3, interferon-alpha, MHC class I upregulation ^[30]^B3b^[35]^D5. 3) Chemokine-driven recruitment (CXCL9, CXCL10, CXCL11 via CXCR3) ^[46]^D5. 4) Effector mechanisms: CD8+ T-cells kill via perforin/granzyme, Fas-FasL; cytokines (TNF-alpha, IFN-alpha, IL-1beta) induce apoptosis via JNK/BIM ^[36]^B3b. 5) Beta-cell loss: ~80-90% destroyed before clinical hyperglycemia. Biochemical signature: hyperglycemia with absolute insulin deficiency. Fasting glucose ≥7.0 mmol/L (126 mg/dL) or random ≥11.1 mmol/L (200 mg/dL) with symptoms. Low/undetectable C-peptide (<0.2 nmol/L fasting, <0.6 nmol/L after mixed-meal). Positive islet autoantibodies (≥1 of GAD65, IA-2, ZnT8, IAA) in >90% new-onset. Ketosis/ketoacidosis (beta-hydroxybutyrate ≥3.0 mmol/L) ^[41]^C4. Fulminant T1DM: rapid destruction, no autoantibodies, normal HbA1c at presentation, linked to HCMV ^[24]^C4. LADA: slow progression, detectable C-peptide for years ^[7]^D5. Systemic consequences: hyperglucagonemia, proteolysis, lipolysis, growth hormone-IGF-I axis suppression (low IGF-I, increased fracture risk) ^[27]^D5, soluble leptin receptor elevation ^[29]^B3b, altered bone marrow adiposity ^[25]^D5. Pearl: The biochemical signature of T1DM is absolute insulin deficiency confirmed by undetectable C-peptide with hyperglycemia and ketosis, underpinned by an autoimmune process targeting β-cell antigens GAD65, IA-2, ZnT8, or insulin, a pattern that distinguishes it from all other forms of diabetes.

Key Autoantigens in Type 1 Diabetes

Autoantigen	Prevalence (%) in New-Onset T1DM	Comments
GAD65 (glutamic acid decarboxylase)	70-80	Most common; persists for years; found also in stiff-person syndrome
IA-2 (insulinoma-associated protein 2)	60-70	Protein tyrosine phosphatase; high specificity for T1DM
ZnT8 (zinc transporter 8)	60-80	Polymorphic (R/W/Q alleles); screening improves detection
Insulin/Preproinsulin	50-70	Younger age at onset correlates with higher prevalence; first antibody to appear in children ^[7]^D5

Epidemiology, Etiology and Risk Factors

▸Incidence rising 3-4% per year; highest in Finland, lowest in China.
▸Genetic risk: HLA-DR3/4-DQ2/8 heterozygosity OR >20; environmental triggers include enterovirus, caesarean section, vitamin D insufficiency.

HY High Yield: Childhood vaccinations (MMR, BCG) do not increase T1DM risk [57].

Global incidence rising 3-4% per year ^[2]^A1a. Highest in Finland (64.2 per 100,000 person-years in children <15), lowest in China and Venezuela (<1 per 100,000) ^[2]^A1a^[76]^D5. Global average ~15 per 100,000 children. Prevalence in Europe/North America 0.2-0.5%; 1.45 million in U.S. (2020) ^[2]^A1a^[76]^D5. Age peaks: 4-6 years and 10-14 years ^[76]^D5. Before puberty, equal sex incidence; after 15, male predominance (1.5:1) ^[58]^B2a^[76]^D5. Girls have higher HbA1c and more DKA (diabulimia) ^[58]^B2a^[74]^D5^[84]^B2b. Incidence in children <5 doubled since 1990s ^[2]^A1a^[76]^D5. Etiology: autoimmune (>95% childhood-onset) ^[76]^D5; iatrogenic (checkpoint inhibitor-induced, 0.2-0.9% of ICI recipients, median onset 3-4 weeks, >50% present with DKA) ^[20]^C4^[66]^B2b; genetic (monogenic forms like MODY, 1-2% of all diabetes) ^[64]^D5; other (pancreatitis, pancreatectomy, cystic fibrosis-related diabetes) ^[64]^D5^[81]^A1a. Risk factors: genetic (HLA-DR3-DQ2/DR4-DQ8 OR 5-10, both haplotypes OR >20) ^[76]^D5; non-HLA genes (INS, PTPN22, CTLA4, IL2RA OR 1.1-1.5) ^[76]^D5. Environmental: caesarean section (OR 1.23) ^[60]^B3a, early term birth (RR 1.33) ^[50]^B2a, enteroviral infection (OR 2-3) ^[76]^D5, vitamin D insufficiency (OR 2-4) ^[68]^B3b, ICI therapy (HR 2.0) ^[66]^B2b, Down syndrome (IRR 3.67) ^[53]^B2b. Vaccination (MMR, BCG) shows no association ^[57]^B3a. Seasonal variation: peak in autumn/winter ^[76]^D5. Pearl: The rapid global rise in T1DM incidence (3-4% per year) is too fast for genetic change and implicates environmental triggers, most consistently enteroviral infection in early childhood, while reassuringly, childhood vaccinations do not increase risk ^[2]^A1a^[57]^B3a^[76]^D5.

Risk Factors for Type 1 Diabetes Mellitus

Factor	OR / RR	Evidence Level	Source
HLA-DR3/4-DQ2/8 heterozygosity	OR 20+	2b	^[76]^D5
First-degree relative with T1DM	RR 15	2b	^[76]^D5
Caesarean section delivery	OR 1.23 (95% CI 1.10-1.38)	3a (meta-analysis, 20 studies)	^[60]^B3a
Early term birth (37-38 weeks)	RR 1.33 (95% CI 1.17-1.51)	2a (meta-analysis)	^[50]^B2a
Enteroviral infection (in pregnancy or early childhood)	OR 2-3	2b	^[76]^D5
Vitamin D insufficiency	OR 2-4	3b	^[68]^B3b
ICI therapy (PD-1/PD-L1)	HR 2.0 vs. no ICI	2b	^[66]^B2b
Down syndrome	IRR 3.67 (95% CI 2.43-5.55)	2b (registry, UK)	^[53]^B2b
Vaccination (routine childhood)	No increased risk (OR 1.0)	3a (meta-analysis, 23 studies)	^[57]^B3a

Clinical Presentation

▸Classic triad: polyuria, polydipsia, weight loss; symptom duration 2-6 weeks in children.
▸Atypical presentations: bilateral cataracts, ICI-induced, MIS-C; red flags include Kussmaul respirations, altered consciousness, hypokalemia.

! Warning: Hypokalemia (K+ <3.0 mEq/L) is a contraindication to insulin therapy until potassium is repleted.

Classic tetrad: polyuria, polydipsia, polyphagia, unintentional weight loss (5-10% body weight over weeks). Polyuria often manifests as nocturia or nocturnal enuresis in children. Symptom duration typically 2-6 weeks in children; adults may have more insidious course over months ^[3]^B3b^[90]^D5. Blurred vision from osmotic lens swelling. Fatigue, weakness, nausea, vomiting with ketosis. Vaginal candidiasis in females. DKA presentation: Kussmaul respirations, fruity acetone breath, abdominal pain, vomiting, tachycardia, hypotension, altered mental status progressing to coma. DKA severity: mild (pH 7.2-7.3), moderate (pH 7.1-7.2), severe (pH <7.1). Physical exam: signs of dehydration; in DKA: tachycardia, hypotension, tachypnea, hypothermia. Mental status ranges from alert to obtundation. Cerebral edema in children: headache, vomiting, bradycardia, hypertension (Cushing's triad), declining consciousness. Abdomen: diffuse tenderness, diminished bowel sounds. Skin: poor turgor, cool, mottled; acanthosis nigricans absent (suggests insulin resistance). Fundoscopic exam normal at diagnosis. Atypical presentations: pediatric cataracts (bilateral, can be sole presenting sign) ^[96]^C4; COVID-19-related MIS-C with new-onset T1DM in severe DKA, non-fluid responsive shock ^[86]^C4; ICI-induced T1DM (~0.2% on PD-1 inhibitors, abrupt hyperglycemia and DKA, often negative autoantibodies) ^[22]^C4; acute pancreatitis or pancreatic trauma; transient GADA positivity in MODY ^[94]^C4. Variants: classic acute-onset (most common in children), LADA/SPIDDM (adult-onset, GADA positive, initially non-insulin requiring) ^[3]^B3b, fulminant T1DM (abrupt DKA, undetectable C-peptide, no autoantibodies, elevated pancreatic enzymes, more common in Asians). Red flags: Kussmaul respirations (severe acidosis), altered consciousness (cerebral edema), hemodynamic instability (fluid-refractory shock), severe vomiting, hypokalemia (K+ <3.0 mEq/L contraindicates insulin until repleted). Pearl: The classic symptom triad of polyuria, polydipsia, and weight loss is the hallmark of new-onset T1DM, but in children, nocturnal enuresis can be the earliest clue. Remember that atypical presentations (bilateral cataracts, ICI-induced diabetes, or MIS-C) require a high index of suspicion and immediate insulin initiation to prevent DKA.

Variants of Autoimmune Diabetes

Variant	Key Features	Frequency
Classic (acute-onset) T1DM	Rapid symptom onset (<6 weeks), DKA common, low C-peptide, positive islet autoantibodies	Most common presentation in children and adolescents
Slowly progressive insulin-dependent diabetes mellitus (SPIDDM) / Latent autoimmune diabetes in adults (LADA)	Adult-onset (>30 years), slower progression to insulin dependence (months to years), initially non-insulin requiring, GADA positive. C-peptide is initially detectable but declines ^[3]^B3b	~10% of adults diagnosed with T2DM
Fulminant T1DM	Abrupt onset of DKA within days, undetectable C-peptide, no islet autoantibodies, elevated pancreatic enzymes	Rare, more common in Asian populations

Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization

▸Diagnosis: hyperglycemia + ketosis + positive islet autoantibody (GADA, IA-2A, ZnT8A).
▸Antibody-negative cases: measure C-peptide; if low, consider monogenic diabetes (WFS1, INS, GCK, HNF1A, HNF4A).

HY High Yield: GADA alone misses ~47% of adult-onset T1DM; use panel including IA-2A and ZnT8A for sensitivity 85-90% [75,128].

Diagnosis: hyperglycemia + ketosis + autoimmune beta-cell destruction. Core triad: (1) hyperglycemia meeting diabetes criteria, (2) evidence of insulin deficiency (ketosis, low C-peptide), (3) presence of islet autoantibodies. History: acute-onset polyuria, polydipsia, weight loss, fatigue, blurred vision over days to weeks. ~30-40% children and 20-30% adults present with DKA ^[104]^B2b. Physical exam: volume depletion, acetone breath; family history of autoimmune disease. Gold standard: detection of at least one islet autoantibody (GADA, IA-2A, ZnT8A) in a patient with hyperglycemia and insulin deficiency. Pooled sensitivity of GADA alone for adult-onset T1DM 53% (95% CI 0.4-0.83); specificity >95% ^[75]^B2a. Adding IA-2A and ZnT8A increases sensitivity to 85-90% ^[128]^B3b. ZnT8A useful in antibody-negative cases and may signal concurrent autoimmune thyroiditis ^[129]^B3b. Laboratory studies: fasting glucose ≥126 mg/dL, random glucose ≥200 mg/dL with symptoms, HbA1c ≥6.5% (may be normal early), blood beta-hydroxybutyrate ≥3 mmol/L (DKA), fasting C-peptide <0.2 nmol/L, stimulated C-peptide (MMTT) <0.6 nmol/L at 90 min (gold standard for residual function). Islet autoantibodies: ≥1 positive at diagnosis; may wane over years. Genetic testing (monogenic panel) when antibodies negative and clinical features suggest monogenic diabetes (young age, family history, low insulin requirements); recessive WFS1 mutations found in substantial proportion of antibody-negative Indian children ^[118]^B3b. Imaging: routine imaging plays no role; research PET with radiolabeled exendin or anti-GAD antibodies not clinically available ^[76]^D5. Biopsy/histology: not performed for diagnosis; insulitis on autopsy specimens. Diagnostic algorithm: Step 1: Confirm diabetes (fasting glucose ≥126, random ≥200 with symptoms, or HbA1c ≥6.5%). If DKA, treat emergently. Step 2: Assess ketosis (urine/blood ketones; beta-hydroxybutyrate ≥0.6 mmol/L suggests insulin deficiency, ≥3 mmol/L indicates DKA). Step 3: Measure islet autoantibodies (GADA, IA-2A, ZnT8A). If any positive, confirm autoimmune T1DM. Step 4: If antibodies negative, measure fasting C-peptide. If low (<0.2 nmol/L), consider idiopathic type 1 or monogenic diabetes; perform genetic testing (WFS1, INS, GCK, HNF1A, HNF4A) ^[118]^B3b. If C-peptide normal/high, consider type 2 or MODY. Step 5: Assess residual beta-cell function (optional for clinical care, recommended for staging) with MMTT. Step 6: Screen for associated autoimmune diseases: TSH and TPO antibodies (autoimmune thyroid disease in 15-30%) ^[44]^D5^[116]^B2b; celiac disease with tTG-IgA and total IgA ^[132]^D5; consider Addison's disease (early-morning cortisol, adrenal antibodies) if symptoms ^[71]^B2b. First-line treatment at diagnosis: insulin therapy immediately. For patients without DKA, start basal-bolus insulin at total daily dose 0.5-1.0 U/kg/day (50% basal, 50% prandial). For children metabolically stable, home-based management with outpatient education is safe ^[134]^A1a. Offer CGM at diagnosis ^[105]^A1a^[106]^A1a. Pearl: The diagnosis of type 1 diabetes is confirmed by the presence of at least one islet autoantibody (GADA, IA-2A, ZnT8A) in a patient with hyperglycemia and low C-peptide; genetic testing for monogenic diabetes is essential in antibody-negative cases, especially in children ^[75]^B2a^[118]^B3b.

Laboratory Tests for Diagnosis of Type 1 Diabetes

Test	Finding in T1DM	Timing	Sensitivity / Specificity
Fasting plasma glucose	≥126 mg/dL (7.0 mmol/L)	Any	High for diabetes, not specific for type
Random plasma glucose	≥200 mg/dL (11.1 mmol/L) with symptoms	At presentation	High for diabetes
HbA1c	≥6.5% (48 mmol/mol)	May be normal early; rises over weeks	Moderate sensitivity early
Blood beta-hydroxybutyrate	≥3 mmol/L (DKA) or elevated	At presentation	High for ketosis
Fasting C-peptide	<0.2 nmol/L (0.6 ng/mL)	After glycemic control	High for insulin deficiency
Stimulated C-peptide (MMTT)	<0.6 nmol/L (1.8 ng/mL) at 90 min	Within 3 months of diagnosis	Gold standard for residual function
Islet autoantibodies (GADA, IA-2A, ZnT8A)	≥1 positive	At diagnosis; may wane over years	Sensitivity 85-90% combined; specificity >95%
Genetic testing (monogenic panel)	Pathogenic variant in WFS1, INS, GCK, etc.	When antibodies negative	Depends on gene

Severity, Staging and Risk Stratification

▸Staging: Stage 1 (autoantibodies, normoglycemia) to Stage 3 (clinical onset).
▸Glycemic targets: HbA1c <7.0% adults, <7.5% children; CGM reduces severe hypoglycemia by 40-50%.

HY High Yield: DCCT: intensive control (HbA1c <7.0%) reduces retinopathy by 76%, nephropathy by 54%, neuropathy by 60% [148].

Staging: Stage 1 (≥2 islet autoantibodies, normoglycemia); Stage 2 (autoantibodies + dysglycemia: IFG/IGT/HbA1c 5.7-6.4%); Stage 3 (clinical onset with symptomatic hyperglycemia) ^[142]^B2b. Screening first-degree relatives reveals autoantibody positivity in 3-8% of children aged 2-18 years ^[145]^C4. Children seroconverting to multiple autoantibodies before age 3 have highest risk of rapid progression ^[142]^B2b. Glycemic targets: ADA recommends HbA1c <7.0% for most nonpregnant adults; <7.5% for children and adolescents; less stringent (<8.0%) for those with severe hypoglycemia history or advanced complications ^[1]^B2c. DCCT: intensive control (HbA1c <7.0%) reduces retinopathy by 76%, nephropathy by 54%, neuropathy by 60% ^[148]^A1a. Risk stratification for acute complications: DKA 30-day readmission rate 18.5% ^[4]^B2c; predictors include younger age, female sex, lower income, comorbid depression. Hypoglycemia risk: machine learning model (AUC 0.82) identifies low HbA1c, longer duration, renal impairment, certain insulin regimens ^[149]^B2b. CGM reduces severe hypoglycemia by 40-50% ^[106]^A1a. Chronic microvascular complications: retinopathy incidence 12.5% over 10 years in Saudi cohort ^[82]^B3b; retinal vascular fractal dimension independently predicts proliferative retinopathy and nephropathy (OR 2.1 per SD decrease) ^[144]^B2b. Nephropathy: annual screening for albuminuria and eGFR; ACEi/ARB for albuminuria. Neuropathy: risk factors include longer duration, poor control, other microvascular complications; cognitive dysfunction with gray matter deficits ^[115]^D5. Special populations: pregnancy - preconception HbA1c <6.5% reduces congenital malformations ^[14]^A1c^[15]^A1c; maternal T1DM associated with atopic dermatitis in offspring (aOR 1.3) ^[9]^B2b and higher maternal depression ^[34]^D5. Comorbid autoimmune conditions: celiac disease and autoimmune thyroid disease common; anti-GAD and anti-insulin antibodies correlate with more severe histopathological changes in celiac disease ^[12]^B3b. Risk prediction tools: autoantibody trajectory clustering for time to clinical onset ^[142]^B2b; retinal fractal analysis ^[144]^B2b; machine learning for hypoglycemia ^[149]^B2b. Pearl: Risk stratification in type 1 diabetes spans pre-symptomatic autoantibody staging, glycemic targets that balance microvascular protection against hypoglycemia, and complication-specific predictors such as retinal fractal dimension for retinopathy and machine learning models for hypoglycemia; these tools guide treatment intensity and surveillance intervals ^[142]^B2b^[144]^B2b^[149]^B2b.

Staging of Type 1 Diabetes

Stage	Autoantibodies	Glycemic Status	Clinical Implications
1	≥2 positive	Normoglycemia	Highest risk for progression; candidate for prevention trials
2	≥2 positive	Dysglycemia (IFG/IGT/HbA1c 5.7-6.4%)	Very high risk; consider metformin or immunomodulation in trials
3	Positive (often)	Overt hyperglycemia (HbA1c ≥6.5% or symptoms)	Clinical diagnosis; initiate insulin therapy

Acute Management and Endocrine Emergencies

▸DKA: fluid resuscitation (0.9% NaCl 15-20 mL/kg), then IV insulin 0.1 U/kg bolus + 0.1 U/kg/h infusion.
▸Severe hypoglycemia: oral glucose 15-20 g if conscious; glucagon 1 mg IM or IV dextrose 50% if unconscious.

! Warning: Do not use bicarbonate routinely in DKA; reserve for pH <6.9. Do not stop insulin infusion prematurely.

DKA: most common life-threatening emergency in T1DM, incidence 1-5% per patient-year ^[104]^B2b. Diagnosis: hyperglycemia (glucose >250 mg/dL), ketosis (beta-hydroxybutyrate ≥3 mmol/L or moderate-to-large urine ketones), metabolic acidosis (venous pH <7.3, bicarbonate <15 mEq/L). Severity: mild (pH 7.25-7.30, bicarb 15-18), moderate (pH 7.00-7.24, bicarb 10-14), severe (pH <7.00, bicarb <10). Concurrent HHS possible. Initial assessment: volume status, mental state, precipitating factors (infection, insulin omission, new-onset, MI, SGLT2 inhibitor use) ^[150]^A1a. In children, AKI present in up to 40% ^[152]^B2b. First-line intervention: fluid resuscitation - 0.9% NaCl 15-20 mL/kg over first hour (1 L in adults). Subsequent fluids based on corrected sodium: if normal/elevated, use 0.45% saline; if low, continue 0.9% saline. Infusion rate 250-500 mL/h for next 4 hours, then replace half deficit over 8 hours, remainder over 16 hours. Do not use bicarbonate routinely. Insulin therapy: after fluid resuscitation, regular insulin 0.1 U/kg IV bolus, then continuous IV infusion 0.1 U/kg/h. If severe DKA with hypokalemia (K+ <3.3 mEq/L), hold insulin and correct potassium first. When glucose falls to 250 mg/dL, add 5% dextrose to IV fluids and reduce insulin to 0.05-0.1 U/kg/h to maintain glucose 150-200 mg/dL until acidosis resolves. Potassium replacement: when K+ <5.3 mEq/L, add 20-30 mEq KCl or K phosphate per liter IV fluid; target K+ 4-5 mEq/L; monitor every 2 hours. Bicarbonate: reserve for pH <6.9; give 50-100 mEq NaHCO3 in 200 mL sterile water over 30-60 minutes with ECG monitoring; evidence does not support routine use ^[148]^A1a. Second-line: if no improvement after 2-4 hours, reassess for inadequate insulin delivery, infection, occult MI, cerebral edema (in children: altered mental status, bradycardia, hypertension; treat with mannitol 0.5-1 g/kg IV or hypertonic saline). Increase insulin to 0.15 U/kg/h if no response. Monitoring: blood glucose hourly until stable, then every 2 hours; electrolytes every 2-4 hours; venous pH every 2-4 hours until pH >7.3; anion gap every 2 hours; resolution defined as anion gap <12 mEq/L or bicarbonate >18 mEq/L and pH >7.3; continuous ECG for hypokalemia/hyperkalemia. Transition to subcutaneous insulin: overlap IV insulin with SC insulin by 1-2 hours. For MDI, give basal insulin (e.g., glargine U-100 0.2-0.3 U/kg) 2 hours before stopping IV. For pump, restart with usual basal rate and correction bolus. Do not stop IV insulin until SC insulin active for at least 1 hour. Severe hypoglycemia (glucose <54 mg/dL or requiring external assistance): if conscious, give 15-20 g oral glucose (4 oz juice, 3-4 glucose tablets); recheck in 15 minutes; repeat if still <70 mg/dL. If unconscious/unable to swallow: glucagon 1 mg IM (or intranasal 3 mg) or IV dextrose 50% 25 g (50 mL). After recovery, provide complex carbohydrate snack. Identify cause: insulin excess, missed meal, exercise, alcohol, gastroparesis. CGM with low-glucose alerts reduces severe hypoglycemia risk by 40-50% ^[166]^B2b. What NOT to do: do not use bicarbonate routinely; do not administer long-acting insulin during acute DKA; do not stop insulin infusion prematurely; do not use SGLT2 inhibitors during acute illness; do not give glucagon to patients with known pheochromocytoma or insulinoma. Pearl: The cornerstone of DKA management is aggressive fluid resuscitation followed by low-dose IV insulin infusion, with potassium replacement guided by hourly monitoring; avoid routine bicarbonate and ensure a 1-2 hour overlap when transitioning to subcutaneous insulin to prevent rebound ketoacidosis ^[104]^B2b^[148]^A1a.

DKA Severity Classification and Disposition

Severity	Venous pH	Serum bicarbonate (mEq/L)	Disposition
Mild	7.25-7.30	15-18	Ward or step-down unit
Moderate	7.00-7.24	10-14	Step-down or ICU
Severe	<7.00	<10	ICU

Dosing for DKA Management

Intervention	Starting dose	Target / max dose	Renal adjustment	Hepatic adjustment	Key monitoring
0.9% saline	15-20 mL/kg IV over 1 h	250-500 mL/h thereafter	No adjustment	No adjustment	Urine output, serum Na+, osmolality
Regular insulin IV	0.1 U/kg bolus + 0.1 U/kg/h infusion	0.05-0.15 U/kg/h to maintain glucose 150-200 mg/dL	No adjustment	No adjustment	Glucose hourly, K+ every 2 h, pH every 2-4 h
Potassium chloride	20-30 mEq/L IV fluid when K+ <5.3 mEq/L	Target K+ 4-5 mEq/L	Reduce if eGFR <30	No adjustment	K+ every 2 h, ECG
Sodium bicarbonate	50-100 mEq IV over 30-60 min (only if pH <6.9)	Single dose; reassess pH	No adjustment	No adjustment	pH, K+, Ca2+, ECG
Glucagon (for severe hypoglycemia)	1 mg IM or intranasal 3 mg	Single dose; may repeat once after 15 min	No adjustment	No adjustment	Glucose at 15 min, mental status

Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)

▸Glycemic target: HbA1c <7.0% adults, <7.5% children; TIR >70%.
▸AHCL systems preferred; CGM standard; SGLT2i increase DKA risk 3.5-fold, not recommended.

Rx Drug of Choice: Basal insulin: degludec U100 0.2-0.4 U/kg once daily (lower nocturnal hypoglycemia vs glargine) [178]. Prandial: rapid-acting analogues (lispro, aspart) 0.05-0.15 U/kg per meal.

Principle: replace insulin as physiologically as possible. Glycemic target: HbA1c <7.0% (<53 mmol/mol) for most nonpregnant adults; <7.5% for children ^[1]^B2c. Time-in-range (TIR 70-180 mg/dL) >70% correlates with HbA1c <7.0% ^[114]^D5. Insulin delivery: multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII, pump). Basal insulin options: glargine U100, detemir, degludec U100 (starting dose 0.2-0.4 U/kg once daily) - degludec has lower nocturnal hypoglycemia vs glargine (rate ratio 0.75) ^[178]^A1b. Glargine U300 provides flatter profile ^[169]^A1b. Once-weekly insulins (icodec, efsitora alfa) show non-inferior HbA1c but higher level 2 hypoglycemia (RR 1.42) and level 3 (RR 1.67) ^[184]^A1a^[192]^A1a; ADA does not recommend as first-line ^[1]^B2c. Prandial insulin: rapid-acting analogues (lispro, aspart, glulisine) preferred over regular human insulin; starting dose 0.05-0.15 U/kg per meal. CSII vs MDI: CSII lowers HbA1c by -0.4% and reduces severe hypoglycemia by 20-30% ^[191]^A1a. Advanced hybrid closed-loop (AHCL) systems (MiniMed 780G, Tandem Control-IQ) are preferred therapy; randomized trial showed TIR 71% vs 55% with MDI+SMBG ^[98]^A1b; real-world data sustained TIR improvement from 58.8% to 70.9% ^[113]^B2b. CGM is standard of care; reduces HbA1c by -0.3% in adults ≥25 years ^[102]^A1b^[133]^A1a. Adjunctive pharmacotherapy: SGLT2 inhibitors (dapagliflozin, empagliflozin) reduce HbA1c by -0.37%, weight -2.5 kg, but increase DKA risk 3.5-fold (RR 3.53); NNT for 0.5% HbA1c reduction = 8, NNH for DKA = 28 ^[150]^A1a. FDA label restricts use in T1DM outside clinical trials; ADA advises against routine use ^[1]^B2c. GLP-1 receptor agonists (liraglutide, semaglutide) reduce HbA1c by -0.38%, weight -4.8 kg, but increase GI adverse events by 40%; not recommended by ADA ^[173]^A1a. Metformin: Cochrane review in adolescents showed HbA1c reduction -0.2% but no insulin dose reduction; not routinely recommended ^[188]^A1a. Pramlintide: reduces HbA1c ~0.3-0.4%, promotes weight loss, but requires multiple injections and high nausea; rarely used ^[32]^D5. Exercise management: for AID systems, set temporary higher glucose target (120-150 mg/dL) 60-90 min before exercise; reduce meal bolus by 25-50% for meals within 3 hours of exercise ^[183]^A1c. For MDI, ADREM study showed no dose reduction of degludec needed after aerobic exercise ^[55]^A1b. Definitive therapy: pancreas transplantation indicated for ESRD requiring kidney transplant (SPK) or recurrent severe hypoglycemia despite optimized therapy (PTA) ^[181]^D5^[185]^D5. One-year graft survival >85% for SPK, >75% for PTA; 70% insulin-independent at 5 years ^[185]^D5. Islet transplantation: less invasive, lower long-term insulin-independence (~50% at 5 years), requires lifelong immunosuppression ^[181]^D5^[185]^D5. Special populations: pregnancy - preconception HbA1c <6.5% reduces congenital malformations; during pregnancy target HbA1c <6.0% if achievable; CSII or CGM recommended; SGLT2i and GLP-1 RAs contraindicated ^[14]^A1c^[15]^A1c. Pediatrics: insulin dosing weight-based (0.67 IU/kg at age 3-10, 0.96 IU/kg at 11-18) ^[182]^B2c; pump therapy first-line for children <7 years; structured transition programs reduce loss-to-follow-up ^[187]^A1a. Sick-day management: never omit basal insulin; increase monitoring to every 2-4 hours; check ketones; increase total daily insulin by 20-50%; if ketones >1.5 mmol/L or vomiting, seek emergency care ^[1]^B2c. What NOT to do: do not use bicarbonate for DKA unless pH <6.9; do not use SGLT2i routinely; do not omit basal insulin during illness; do not rely solely on HbA1c - use CGM metrics. Pearl: The foundation of type 1 diabetes management is intensive insulin replacement delivered via a basal-bolus regimen titrated to an HbA1c <7.0%, complemented by real-time CGM to maximize time-in-range and minimize hypoglycemia; advanced hybrid closed-loop systems represent the current best technology for achieving these targets safely, and transplantation is reserved for those with ESRD or life-threatening hypoglycemia unresponsive to medical therapy ^[1]^B2c^[102]^A1b^[191]^A1a^[113]^B2b.

Basal insulin dosing for type 1 diabetes

Insulin	Starting dose	Target / max dose	Renal adjustment	Hepatic adjustment	Key monitoring
Insulin degludec (U100)	0.2-0.4 units/kg once daily	Titrate to fasting glucose 80-130 mg/dL; no defined max	No adjustment required	No adjustment required	Fasting glucose, nocturnal hypoglycemia ^[178]^A1b (1b)
Insulin glargine U100	0.2-0.4 units/kg once daily	Same as above	No adjustment	No adjustment	Fasting glucose, injection-site lipodystrophy ^[189]^A1a (1a)
Insulin glargine U300	0.3-0.5 units/kg once daily	Same as above	No adjustment	No adjustment	Fasting glucose, slightly higher dose needed vs U100 ^[169]^A1b (1b)
NPH insulin	0.3-0.5 units/kg once or twice daily	Same as above	No adjustment	No adjustment	Higher nocturnal hypoglycemia risk vs analogues ^[189]^A1a (1a)

History and Evolution of Treatment

▸DCCT: intensive therapy reduces retinopathy 76%, nephropathy 54%, neuropathy 60%.
▸AID systems (MiniMed 780G, Tandem Control-IQ) achieve TIR >70% with less hypoglycemia.

HY High Yield: Teplizumab (2022) is first disease-modifying therapy to delay stage 3 T1DM in at-risk individuals.

Insulin discovered in 1921, transforming T1DM from fatal to manageable. Early beef/pork insulin immunogenic. NPH insulin (1940s) extended duration. Recombinant human insulin (Humulin, 1982) eliminated animal-source immunogenicity. Insulin analogues: lispro (1996), aspart (1999) - rapid absorption, onset 5-15 min, peak 30-90 min, allowing injection immediately before meals ^[198]^A1b. Glargine U100 (2000) - flat, peakless basal profile ~24 hours. Degludec (2012) - ultra-long >42 hours, lower variability (CV 32% vs 54% for glargine) ^[171]^A1b^[178]^A1b. Glargine U300 (2015) - flatter profile, requires ~0.3-0.5 U/kg ^[169]^A1b. DCCT (1993): intensive therapy (MDI or CSII) reduced retinopathy by 76%, nephropathy by 54%, neuropathy by 60% vs conventional ^[201]^B2b. HbA1c 7.2% vs 9.1%; severe hypoglycemia 2-3 fold higher. EDIC follow-up showed metabolic memory - early intensive therapy reduced CVD and all-cause mortality for decades ^[201]^B2b^[67]^B2b. CGM: first system 1999; JDRF CGM Trial (2008) showed HbA1c reduction -0.53% in adults ≥25 years ^[102]^A1b. CSII pumps: STAR 3 Trial (2010) showed sensor-augmented pump (SAP) achieved HbA1c 7.5% vs 8.1% with MDI ^[174]^A1b. Automated insulin delivery (AID): Bionic Pancreas Trial (2014) bihormonal system maintained mean glucose 138 mg/dL with <4% time <60 mg/dL ^[175]^A1b. MiniMed 670G (2016) first hybrid closed-loop; MiniMed 780G (2020) added automated correction boluses; trial showed TIR improvement from 57% to 79% ^[98]^A1b. Tandem Control-IQ (2019) real-world TIR 59% to 71% ^[113]^B2b. DDG/ÖDG guidelines recommend AID as preferred therapy ^[183]^A1c. Abandoned approaches: GAD-alum vaccination (Diamyd) failed Phase 3 ^[103]^A1b^[139]^A1b; anti-CD3 (teplizumab) delayed insulin need but Phase 3 missed primary endpoint; teplizumab FDA-approved 2022 for delaying stage 3 T1DM in at-risk individuals. Rituximab preserved C-peptide at 1 year but no durable effect ^[176]^A1b^[17]^A1b. Abatacept modest C-peptide preservation but no difference in insulin use ^[107]^A1b. DPT-1 trial (2002) oral/subcutaneous insulin did not prevent diabetes ^[200]^A1b. Inhaled insulin (Exubera 2006, Afrezza 2014) - needle-free but poor bioavailability, variable absorption, boxed warning for bronchospasm; Exubera withdrawn 2007 ^[203]^A1b^[207]^A1b. Intermittent IV insulin therapy abandoned with CSII ^[221]^C4. Under investigation: GLP-1 RAs (liraglutide, semaglutide) modest insulin dose reduction, GI side effects ^[16]^A1b^[211]^C4; SGLT2 inhibitors reduce HbA1c ~0.4% but DKA risk 4-6% ^[211]^C4^[222]^D5; prebiotics (oligofructose-enriched inulin) showed modest HbA1c reduction in pilot trial ^[186]^A1b. Pearl: The evolution of type 1 diabetes therapy reflects a relentless pursuit of physiological insulin replacement: from crude animal extracts to recombinant analogues with tailored kinetics, from episodic fingerstick monitoring to real-time CGM, and from open-loop to hybrid closed-loop systems that automate basal delivery. The DCCT established that intensive therapy dramatically reduces complications, and the subsequent technology trials proved that CGM and AID systems can achieve glycemic targets with less hypoglycemia, making normoglycemia an achievable goal for most patients ^[102]^A1b^[174]^A1b^[175]^A1b^[98]^A1b.

Evolution of Insulin Preparations

Era	Preparation	Key Feature	Clinical Impact
1920s	Animal insulin (beef/pork)	First life-saving therapy	Transformation from fatal to chronic disease
1940s	NPH	Protamine suspension extends duration	Reduced injection frequency
1982	Recombinant human insulin	No animal immunogenicity	Eliminated allergy and lipodystrophy
1996	Lispro	Rapid onset (5-15 min)	Postprandial injection possible
2000	Glargine U100	Peakless 24-h basal	Replaced NPH's unpredictable peak
2012	Degludec	Ultra-long (>42 h), low variability	Reduced nocturnal hypoglycemia ^[178]^A1b
2015	Glargine U300	Flatter, longer profile vs U100	Smoother 24-h coverage ^[169]^A1b

Multiglandular Syndromes, Genetic Context and Co-Axis Effects

▸Screen for autoimmune thyroid disease, celiac disease, and adrenal insufficiency in all T1DM patients.
▸Antibody-negative T1DM in children: consider WFS1 mutations (Wolfram syndrome) for anticipatory care.

! Warning: Missed adrenal insufficiency can be fatal during intercurrent illness; screen with early-morning cortisol and ACTH if symptoms present.

Autoimmune polyglandular syndromes (APS) account for 12% of patients with at least one autoimmune endocrine disorder; ~5.4% of T1DM patients have at least one additional autoimmune disease ^[223]^C4^[116]^B2b. APS type 1 (APECED): triad of chronic mucocutaneous candidiasis, hypoparathyroidism, Addison disease; T1DM in ~12-18%, often antibody-negative, fulminant. APS type 2 (Schmidt syndrome): Addison disease plus T1DM or autoimmune thyroid disease. DPV registry (n=6166 T1DM with additional autoimmune disease): Hashimoto thyroiditis most frequent (63%), followed by Graves disease (4.6%), Addison disease (0.5%) ^[116]^B2b. Screening: TSH and TPO antibodies at diagnosis and periodically; celiac serology (tTG-IgA); if thyroid disease present, screen for Addison (early-morning cortisol, ACTH, 21-hydroxylase antibodies) - missed adrenal insufficiency can cause life-threatening hypoglycemia. Co-axis effects: thyroid dysfunction - thyrotoxicosis worsens hyperglycemia, hypothyroidism increases hypoglycemia risk. Euthyroid sick syndrome (ESS) occurs in 50-70% of pediatric DKA admissions, resolves within two weeks in 86% ^[92]^B2b. Gonadal axis: PCOS substantially more prevalent in women with T1DM (up to 47% in premenarchal onset) ^[18]^D5^[224]^C4; mechanism: supraphysiologic exogenous insulin stimulates ovarian and adrenal androgen production. Diagnosis per Rotterdam criteria; measure total testosterone, SHBG, DHEAS. Metformin co-therapy may improve menstrual regularity, though not FDA-approved. Adrenal axis: Addison disease in T1DM rare (0.5%) but deadly if missed; nightly hypoglycemia, hyponatremia, hyperkalemia, unexplained fatigue should prompt ACTH stimulation test (high-dose 250 mcg; peak cortisol <18 mcg/dL confirms insufficiency). Genetic context: WFS1 mutations (Wolfram syndrome) - among antibody-negative Indian children, 20% harbored biallelic WFS1 mutations ^[118]^B3b; presents with insulin-deficient diabetes in first decade, often before optic atrophy or hearing loss. Trisomy 21 (Down syndrome): T1DM incidence 3.67-fold higher, younger median age ^[53]^B2b; screen for autoimmune thyroid disease and celiac disease. Fulminant T1DM: rapid beta-cell destruction within days, HCMV antigen in islets, upregulation of ZBP1 and RIG-I ^[24]^C4. Co-axis effects on pregnancy: maternal T1DM increases risk of preterm birth (aRR 1.51), low birth weight (aRR 1.55), stillbirth (aRR 1.45) ^[83]^B2b; prenatal exposure associated with autism (OR 1.30) and ADHD (OR 1.15) in offspring ^[165]^B2b. Preconception optimization: HbA1c <6.5%, TIR >70%, TSH screening mandatory ^[217]^A1c. Pearl: Even after establishing a T1DM diagnosis, the clinician must screen for autoimmune thyroid disease, celiac disease, and adrenal insufficiency; a missed diagnosis of adrenal insufficiency can be fatal during intercurrent illness, while recognition of monogenic forms (e.g., WFS1 mutations in antibody-negative children) enables anticipatory care for vision and hearing loss ^[116]^B2b^[118]^B3b.

Frequency of Additional Autoimmune Diseases in Type 1 Diabetes (DPV Registry)

Autoimmune Disease	Proportion of T1DM-AID Patients (n=6166)	Key Screening Test
Hashimoto thyroiditis	63%	TSH, TPO antibodies
Graves disease	4.6%	TSH, TRAb
Addison disease	0.5%	Morning cortisol, ACTH, 21-OH antibodies

Complications and Long-term Sequelae

▸Annual screening for albuminuria, retinopathy, neuropathy starting 5 years after diagnosis.
▸Severe hypoglycemia increases all-cause mortality 2.7-fold; CGM reduces severe hypoglycemia by 40-60%.

HY High Yield: DCCT/EDIC: intensive therapy reduces retinopathy 76%, nephropathy 54%, CVD 42% [230].

Micro- and macrovascular complications remain dominant morbidity and mortality sources. DCCT/EDIC: intensive therapy reduces retinopathy by 76%, nephropathy by 54%, CVD by 42% ^[230]^D5. Residual risk persists despite HbA1c target. Microvascular: diabetic kidney disease (DKD) - prevalence CKD G3-G5 6.7%, ESRD 0.7% in SDRNT1BIO ^[232]^B2b. Annual screening for UACR and eGFR starting 5 years after diagnosis. ACEi/ARB first-line when UACR >30 mg/g ^[1]^B2c. Diabetic retinopathy (DR) - leading cause of preventable blindness in working-age adults. 10% reduction in mean HbA1c reduces DR risk by ~40% ^[230]^D5. Screening: dilated fundoscopy or retinal photography within 5 years of diagnosis in adults, at age 11 in children with ≥2 years duration, then annually ^[1]^B2c. For proliferative DR or diabetic macular edema: anti-VEGF therapy and panretinal photocoagulation. Diabetic neuropathy - peripheral symmetric polyneuropathy, autonomic neuropathy, mononeuropathies. Cardiovascular autonomic neuropathy (CAN) affects 20-30% after 10 years, associated with higher IL-6 ^[228]^C4; doubles risk of silent myocardial ischemia and sudden cardiac death. Annual screening for distal symmetric polyneuropathy with 10-g monofilament and 128 Hz tuning fork starting 5 years after diagnosis. Treatment: pregabalin 75-150 mg twice daily or duloxetine 30-60 mg once daily for neuropathic pain ^[1]^B2c. Macrovascular: CVD accounts for ~60% of deaths in T1DM ^[150]^A1a. Relative risk for CVD 10-fold higher in women, 3-4 fold higher in men ^[167]^A1b. FOURIER trial: evolocumab reduced primary composite endpoint by 19% in T1DM subset (HR 0.81) ^[167]^A1b. Statins recommended for all T1DM patients aged ≥40 years or younger with risk factors; target LDL <70 mg/dL ^[1]^B2c. SGLT2 inhibitors (dapagliflozin, empagliflozin) reduce cardiovascular death or heart failure hospitalization (HR 0.72) but increase DKA risk 3-fold (NNH 34) ^[150]^A1a^[235]^D5; contraindicated in patients with history of DKA. Hypoglycemia: severe hypoglycemia incidence ~1.0-1.5 episodes per patient-year ^[189]^A1a. Each episode associated with 2.7-fold increased risk of all-cause mortality (HR 2.70) and 2.3-fold increased CVD risk over 5 years ^[214]^B3b. Impaired awareness of hypoglycemia affects 20-40% of patients, increases severe events by 6-fold ^[189]^A1a. CGM reduces time in hypoglycemia by ~50% and severe hypoglycemia by 40-60% ^[133]^A1a^[166]^B2b. Structured education (DAFNE) reduces hypoglycemia ^[230]^D5. Bone health: 6-fold increased risk of hip fracture ^[27]^D5; decreased BMD, impaired bone turnover. Screen with DXA in postmenopausal women and men ≥50 years; bisphosphonates first-line for osteoporosis ^[27]^D5. Cognitive dysfunction: DCCT/EDIC cohort shows smaller brain volumes, lower gray matter, higher white matter hyperintensities, associated with neurocognitive deficits ^[67]^B2b^[115]^D5. Autonomic neuropathy: silent myocardial ischemia, gastroparesis, bladder dysfunction; treatment includes prokinetic agents (metoclopramide 5-10 mg before meals) and intermittent catheterization ^[228]^C4. DKA remains leading cause of emergency admission; in Ethiopia, incidence 22.4 per 100 person-years ^[84]^B2b. Pearl: Micro- and macrovascular complications derive from cumulative hyperglycemic exposure and residual risk persists despite optimal HbA1c, so annual screening for albuminuria, retinopathy, and neuropathy is non-negotiable; severe hypoglycemia is a stronger predictor of CVD mortality than HbA1c itself ^[214]^B3b^[230]^D5.

Major Complications of Type 1 Diabetes: Frequency, Prevention, and Management

Complication	Frequency	Key Prevention	Management
Diabetic kidney disease	6.7% (CKD G3-G5) ^[232]^B2b	HbA1c <7%, ACEi/ARB for UACR >30 mg/g	ACEi/ARB, SGLT2 inhibitor (dapagliflozin 5-10 mg daily) ^[235]^D5
Diabetic retinopathy	30% after 20 years ^[230]^D5	Intensive glycemic control, BP control	Anti-VEGF therapy (ranibizumab 0.5 mg monthly) for DME, panretinal photocoagulation for PDR
Cardiovascular autonomic neuropathy	20-30% after 10 years ^[228]^C4	Tight glucose control, avoid hypoglycemia	Fludrocortisone 0.1 mg daily for orthostatic hypotension if needed
Peripheral neuropathy	30-50% ^[1]^B2c	Annual foot exam, glucose optimization	Pregabalin 75-150 mg twice daily or duloxetine 30-60 mg once daily
Cardiovascular disease	60% of mortality ^[150]^A1a	Statin (atorvastatin 20-80 mg daily), LDL <70 mg/dL	PCSK9 inhibitor (evolocumab 140 mg SC q2wk) for high-risk patients ^[167]^A1b

Prognosis, Natural History, Special Populations and Prevention

▸Life expectancy reduced by ~11-13 years; each 1% HbA1c reduction lowers microvascular risk by 30-40%.
▸Preconception HbA1c <6.5% reduces congenital malformations from ~10% to 2-3%.

HY High Yield: Autoantibody screening in first-degree relatives: multiple autoantibody positivity confers 5-year risk ~50% [242].

Without insulin, T1DM is universally fatal within 1-2 years. With modern care, life expectancy reduced by ~11-13 years vs general population, driven by CVD and hypoglycemia-related mortality ^[49]^B2b^[54]^B2b. Natural history: C-peptide responses decline progressively after diagnosis, steepest fall in first 2-5 years ^[90]^D5. Adults have higher residual C-peptide at diagnosis. Autoantibody trajectories stratify risk: children seroconverting to multiple autoantibodies before age 3 have highest risk of rapid progression ^[142]^B2b. Hispanic individuals convert from single to multiple autoantibodies less frequently than non-Hispanic whites, but progression similar once multiple positive ^[242]^B2b. Glycemic control modifies prognosis: each 1% reduction in HbA1c lowers microvascular complication risk by 30-40% ^[80]^A1a. HbA1c variability independently predicts coronary artery calcium and CVD events ^[49]^B2b. Hypoglycemia hospitalization rates in England declined from 1998 to 2013 but remain ~13 per 1000 person-years ^[54]^B2b. Diabetic retinopathy develops in 40-50% after 10 years ^[82]^B3b. Pregnancy: preconception HbA1c <6.5% reduces major congenital malformations from ~10% to 2-3% ^[14]^A1c^[15]^A1c. Insulin requirements change dynamically: peak at week 9, nadir at week 16, then rise 4.08% per week to second peak at week 37 ^[243]^C4. CSII and MDI comparable glycemic outcomes; CSII may reduce hypoglycemia ^[170]^A1a^[180]^B2b. Maternal T1DM increases preeclampsia risk 4-fold ^[19]^B2b^[238]^B2b. Offspring risks: stillbirth, macrosomia, neonatal respiratory distress, congenital malformations ^[51]^B2a. Early-term delivery (37-38 weeks) associated with higher long-term risk of T1DM and obesity in offspring ^[50]^B2a. Maternal T1DM modestly increases atopic dermatitis (aRR 1.12) and neurodevelopmental disorders ^[9]^B2b^[165]^B2b. Contraceptive counseling: combined oral contraceptives not contraindicated but may affect carbohydrate metabolism ^[78]^A1a^[79]^A1a. Pediatric considerations: obesity increases T1DM risk; MIS-C can present with new-onset T1DM in severe DKA ^[86]^C4. Celiac disease autoantibodies spontaneously normalize in up to 14.5% of children despite gluten consumption ^[240]^B2b. Circulating microRNAs (miR-21, miR-126, miR-210) deregulated in pediatric T1DM may serve as early biomarkers ^[177]^C4. Routine screening for MODY using massively parallel sequencing cost-effective ^[89]^B2c. Emphysematous pyelonephritis rare but high mortality ^[91]^C4. Elderly: elevated risks of hypoglycemia and fractures; physical activity reduces hip fracture risk but benefit attenuated with longer diabetes duration ^[239]^B2b. Prevention: screening for islet autoantibodies in first-degree relatives identifies at-risk individuals ^[142]^B2b^[215]^D5. TrialNet Pathway to Prevention: multiple autoantibody positivity confers 5-year risk ~50% ^[242]^B2b. Primary prevention trials (oral insulin, teplizumab) show modest delays; no durable prevention yet ^[215]^D5. Secondary prevention focuses on early glycemic control to preserve residual beta-cell function ^[90]^D5. Noninvasive imaging of beta-cell mass under investigation ^[76]^D5. Pearl: The natural history of type 1 diabetes is defined by progressive beta-cell loss, but early detection through autoantibody screening and aggressive glycemic management can delay complications and improve long-term outcomes ^[90]^D5^[142]^B2b.

References

[1]
Dost A, Bechtold S, Fink K et al.. “2017 American Academy of Pediatrics Clinical Practice Guideline: Impact on Prevalence of Arterial Hypertension in Children and Adolescents With Type 1 Diabetes.” Diabetes care (2020). PMID: 32229598 ↗
L2GUIDELINECited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[2]
de Vries M, Westerink J, Kaasjager KHAH et al.. “Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32827432 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[3]
Wada E, Onoue T, Kinoshita T et al.. “Adult-onset autoimmune diabetes identified by glutamic acid decarboxylase autoantibodies: a retrospective cohort study.” Diabetologia (2021). PMID: 34268631 ↗
L3COHORTCited in: Definition, Classification and Axis Nomenclature, Clinical Presentation
[4]
Shaka H, Aguilera M, Aucar M et al.. “Rate and Predictors of 30-day Readmission Following Diabetic Ketoacidosis in Type 1 Diabetes Mellitus: A US Analysis.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34043791 ↗
L2OTHERCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
[5]
Amato MC, Guarnotta V, Ciresi A et al.. “No phenotypic differences for polycystic ovary syndrome (PCOS) between women with and without type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2013). PMID: 24243639 ↗
L3OTHERCited in: Definition, Classification and Axis Nomenclature
[6]
Codner E, Soto N, Lopez P et al.. “Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2006). PMID: 16569737 ↗
L3OTHERCited in: Definition, Classification and Axis Nomenclature
[7]
Leslie RD, Palmer J, Schloot NC et al.. “Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment.” Diabetologia (2016). PMID: 26498592 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[8]
Marques-Couto P, Afonso J, Coelho-Costa I et al.. “Prevalence and Risk Factors of Diabetic Macular Edema in Type 1 Diabetes: A Systematic Review and Meta-Analysis.” Ophthalmology. Retina (2025). PMID: 41016555 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature
[9]
Weissmann S, Amitai N, Honig E et al.. “Maternal type 1 diabetes mellitus and atopic dermatitis in offspring: A nationwide cohort study.” JAAD international (2026). PMID: 42100114 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention
[10]
Kim KJ, Kim S, Oh R et al.. “High Waist-to-Height Ratio Increases the Risk of Cardiovascular Outcomes in Adults with Type 1 Diabetes Mellitus: A Nationwide Cohort Study.” Diabetes & metabolism journal (2025). PMID: 40904015 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature
[11]
Weng SS, Chien LY. “IVF and risk of Type 1 diabetes mellitus: a population-based nested case-control study.” Human reproduction (Oxford, England) (2024). PMID: 38852062 ↗
L3CASE_CONTROLCited in: Definition, Classification and Axis Nomenclature
[12]
Tetik Dinçer B, Urgancı N, Koç A et al.. “Association of endocrine autoantibodies (anti-TPO, anti-GAD, anti-insulin) with histopathological severity in pediatric Celiac disease: a retrospective cohort study.” BMC pediatrics (2025). PMID: 41430660 ↗
L3COHORTCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
[13]
Zan Y, Wei Y, Zhang W et al.. “Sintilimab-induced diabetes mellitus and thyroid dysfunction in patient with gastric adenocarcinoma: A case report and literature review.” Medicine (2025). PMID: 40388765 ↗
L4SR_OBSCited in: Definition, Classification and Axis Nomenclature
[14]
Wyckoff JA, Lapolla A, Asias-Dinh BD et al.. “Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40652453 ↗
L1GUIDELINECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
[15]
Wyckoff JA, Lapolla A, Asias-Dinh BD et al.. “Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.” European journal of endocrinology (2025). PMID: 40652450 ↗
L1GUIDELINECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
[16]
Pozzilli P, Bosi E, Cirkel D et al.. “Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32219329 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, History and Evolution of Treatment
[17]
Pescovitz MD, Greenbaum CJ, Bundy B et al.. “B-lymphocyte depletion with rituximab and β-cell function: two-year results.” Diabetes care (2013). PMID: 24026563 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[18]
Codner E, Escobar-Morreale HF. “Clinical review: Hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2007). PMID: 17284617 ↗
L5SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
[19]
Du M, Basu A, Fu D et al.. “Serum inflammatory markers and preeclampsia in type 1 diabetes: a prospective study.” Diabetes care (2013). PMID: 23393212 ↗
L2COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention
[20]
de Filette JMK, Pen JJ, Decoster L et al.. “Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.” European journal of endocrinology (2019). PMID: 31330498 ↗
L4SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[21]
Geddes J, Deary IJ, Frier BM. “Effects of acute insulin-induced hypoglycaemia on psychomotor function: people with type 1 diabetes are less affected than non-diabetic adults.” Diabetologia (2008). PMID: 18709352 ↗
L1TRIAL_NONRANDOMCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies
[22]
Clotman K, Janssens K, Specenier P et al.. “Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2018). PMID: 29955867 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[23]
Morkos M, Nensey NK, Bindal A. “Micafungin-Induced Hypoglycemia in a Patient With Type 1 Diabetes: A Case Report and Review of Literature.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30398618 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[24]
Yoneda S, Imagawa A, Fukui K et al.. “A Histological Study of Fulminant Type 1 Diabetes Mellitus Related to Human Cytomegalovirus Reactivation.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28398495 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[25]
Fazeli PK, Horowitz MC, MacDougald OA et al.. “Marrow fat and bone--new perspectives.” The Journal of clinical endocrinology and metabolism (2013). PMID: 23393168 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
[26]
Tomar N, Gupta N, Goswami R. “Calcium-sensing receptor autoantibodies and idiopathic hypoparathyroidism.” The Journal of clinical endocrinology and metabolism (2013). PMID: 23873991 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[27]
Hough FS, Pierroz DD, Cooper C et al.. “MECHANISMS IN ENDOCRINOLOGY: Mechanisms and evaluation of bone fragility in type 1 diabetes mellitus.” European journal of endocrinology (2015). PMID: 26537861 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
[28]
Verrotti A, Scaparrotta A, Olivieri C et al.. “Seizures and type 1 diabetes mellitus: current state of knowledge.” European journal of endocrinology (2012). PMID: 22956556 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
[29]
Kratzsch J, Knerr I, Galler A et al.. “Metabolic decompensation in children with type 1 diabetes mellitus associated with increased serum levels of the soluble leptin receptor.” European journal of endocrinology (2006). PMID: 16990661 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[30]
Assmann TS, Brondani Lde A, Bauer AC et al.. “Polymorphisms in the TLR3 gene are associated with risk for type 1 diabetes mellitus.” European journal of endocrinology (2014). PMID: 24408902 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[31]
Jobanputra R, Sargeant JA, Plekhanova T et al.. “The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-Transporter-2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.” Diabetes/metabolism research and reviews (2026). PMID: 42319968 ↗
L1SR_MA_RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[32]
Frandsen CS, Dejgaard TF, Madsbad S. “Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.” The lancet. Diabetes & endocrinology (2016). PMID: 26969516 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[33]
Elliott J, Sloan G, Stevens L et al.. “Female sex is a risk factor for painful diabetic peripheral neuropathy: the EURODIAB prospective diabetes complications study.” Diabetologia (2023). PMID: 37870649 ↗
L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[34]
Korczak DJ, Pereira S, Koulajian K et al.. “Type 1 diabetes mellitus and major depressive disorder: evidence for a biological link.” Diabetologia (2011). PMID: 21789690 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification
[35]
Pane JA, Coulson BS. “Lessons from the mouse: potential contribution of bystander lymphocyte activation by viruses to human type 1 diabetes.” Diabetologia (2015). PMID: 25794781 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
[36]
Roca-Rivada A, Marín-Cañas S, Colli ML et al.. “Inhibition of the type 1 diabetes candidate gene PTPN2 aggravates TNF-α-induced human beta cell dysfunction and death.” Diabetologia (2023). PMID: 36988639 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[37]
Nieuwdorp M, Holleman F, de Groot E et al.. “Perturbation of hyaluronan metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis.” Diabetologia (2007). PMID: 17415544 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae
[38]
Segev Y, Eshet R, Yakir O et al.. “Systemic and renal growth hormone-IGF1 axis involvement in a mouse model of type 2 diabetes.” Diabetologia (2007). PMID: 17443310 ↗
L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[39]
Kateel R, Parida A, Chogtu B et al.. “Safety of GLP-1 receptor agonists in type 1 diabetes: a systematic review and meta-analysis.” Diabetes research and clinical practice (2026). PMID: 42105869 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies
[40]
Abdel-Rahman SM, Al-Shiab R, Shah E et al.. “Efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta-analysis.” Diabetes, obesity & metabolism (2026). PMID: 41605813 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[41]
Rivetti G, Braile M, Di Sessa A et al.. “Acute Kidney Injury in Children with Polyuria: A Systematic Review.” Journal of clinical medicine (2026). PMID: 41517599 ↗
L4SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[42]
Jawad M, Afaq S, Hussain S et al.. “Effect of digital interventions on adherence to the management of type 1 diabetes mellitus patients: a systematic review.” BMC endocrine disorders (2025). PMID: 41462455 ↗
L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[43]
Chen Y, Tang Y, Yue R et al.. “Effect of Glucagon-Like Peptide-1 Receptor Agonists on Cardiometabolic Risk Factors in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.” Diabetes/metabolism research and reviews (2026). PMID: 41331723 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[44]
Biondi B, Kahaly GJ, Robertson RP. “Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders.” Endocrine reviews (2019). PMID: 30649221 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention
[45]
Meijnikman AS, Gerdes VE, Nieuwdorp M et al.. “Evaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans.” Endocrine reviews (2018). PMID: 29309555 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
[46]
Rotondi M, Chiovato L, Romagnani S et al.. “Role of chemokines in endocrine autoimmune diseases.” Endocrine reviews (2007). PMID: 17475924 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
[47]
Hbibi M, Elamine A, Benhsaien I et al.. “Case Report: Different faces of LRBA deficiency in five Moroccan families.” Frontiers in immunology (2026). PMID: 42148132 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[48]
Al Hayek A, Robert AA, Al Burayk AK et al.. “Comparative Clinical and Metabolic Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Type 1 Diabetes: A Retrospective Cohort Study from Saudi Arabia.” Current diabetes reviews (2026). PMID: 41691684 ↗
L2COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[49]
Horton WB, Snell-Bergeon JK. “Hemoglobin A1c Variability Metrics Predict Coronary Artery Calcium and Cardiovascular Events in Type 1 Diabetes: The CACTI Study.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36637994 ↗
L2TRIAL_NONRANDOMCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
[50]
Tsaitlin-Mor L, Cahen-Peretz A, Bentov Y et al.. “Long-term Risk for Type 1 Diabetes and Obesity in Early Term Born Offspring: A Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38079466 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention
[51]
Balsells M, García-Patterson A, Gich I et al.. “Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis.” The Journal of clinical endocrinology and metabolism (2009). PMID: 19808847 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
[52]
Nicholson WK, Robinson KA, Smallridge RC et al.. “Prevalence of postpartum thyroid dysfunction: a quantitative review.” Thyroid : official journal of the American Thyroid Association (2006). PMID: 16839259 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
[53]
Aslam AA, Baksh RA, Pape SE et al.. “Diabetes and Obesity in Down Syndrome Across the Lifespan: A Retrospective Cohort Study Using U.K. Electronic Health Records.” Diabetes care (2022). PMID: 36178378 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention
[54]
Zhong VW, Juhaeri J, Cole SR et al.. “Incidence and Trends in Hypoglycemia Hospitalization in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study.” Diabetes care (2017). PMID: 28716781 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention
[55]
Drenthen LCA, Ajie M, Abbink EJ et al.. “No insulin degludec dose adjustment required after aerobic exercise for people with type 1 diabetes: the ADREM study.” Diabetologia (2023). PMID: 36879098 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[56]
Bo S, Gentile L, Castiglione A et al.. “C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up.” European journal of endocrinology (2012). PMID: 22577110 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
[57]
Morgan E, Halliday SR, Campbell GR et al.. “Vaccinations and childhood type 1 diabetes mellitus: a meta-analysis of observational studies.” Diabetologia (2015). PMID: 26564178 ↗
L3SR_OBSCited in: Epidemiology, Etiology and Risk Factors
[58]
de Vries SAG, Verheugt CL, Mul D et al.. “Do sex differences in paediatric type 1 diabetes care exist? A systematic review.” Diabetologia (2023). PMID: 36700969 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[59]
Jeitler K, Horvath K, Berghold A et al.. “Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis.” Diabetologia (2008). PMID: 18351320 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[60]
Cardwell CR, Stene LC, Joner G et al.. “Caesarean section is associated with an increased risk of childhood-onset type 1 diabetes mellitus: a meta-analysis of observational studies.” Diabetologia (2008). PMID: 18292986 ↗
L3SR_OBSCited in: Epidemiology, Etiology and Risk Factors
[61]
Stagnaro-Green A. “Approach to the patient with postpartum thyroiditis.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22312089 ↗
L5CASE_REPORTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[62]
Chou IC, Wang CH, Lin WD et al.. “Risk of epilepsy in type 1 diabetes mellitus: a population-based cohort study.” Diabetologia (2016). PMID: 27030312 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
[63]
Dafoulas GE, Toulis KA, Mccorry D et al.. “Type 1 diabetes mellitus and risk of incident epilepsy: a population-based, open-cohort study.” Diabetologia (2016). PMID: 27796422 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[64]
Mikłosz A, Chabowski A. “Adipose-derived Mesenchymal Stem Cells Therapy as a new Treatment Option for Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36916961 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[65]
Li FR, Hukportie DN, Yang J et al.. “Microvascular Burden and Incident Heart Failure Among Middle-Aged and Older Adults With Type 1 or Type 2 Diabetes.” Diabetes care (2022). PMID: 35944243 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors
[66]
Chen X, Affinati AH, Lee Y et al.. “Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes.” Diabetes care (2022). PMID: 35238899 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
[67]
Jacobson AM, Braffett BH, Erus G et al.. “Brain Structure Among Middle-aged and Older Adults With Long-standing Type 1 Diabetes in the DCCT/EDIC Study.” Diabetes care (2022). PMID: 35699949 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, Complications and Long-term Sequelae
[68]
Tamer G, Arik S, Tamer I et al.. “Relative vitamin D insufficiency in Hashimoto's thyroiditis.” Thyroid : official journal of the American Thyroid Association (2011). PMID: 21751884 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors
[69]
Denzer C, Karges B, Näke A et al.. “Subclinical hypothyroidism and dyslipidemia in children and adolescents with type 1 diabetes mellitus.” European journal of endocrinology (2013). PMID: 23384709 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
[70]
Sahakyan K, Klein BE, Lee KE et al.. “Inflammatory and endothelial dysfunction markers and proteinuria in persons with type 1 diabetes mellitus.” European journal of endocrinology (2010). PMID: 20332124 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors
[71]
Chantzichristos D, Persson A, Eliasson B et al.. “Incidence, prevalence and seasonal onset variation of Addison's disease among persons with type 1 diabetes mellitus: nationwide, matched cohort studies.” European journal of endocrinology (2017). PMID: 29066573 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[72]
Okosieme OE, Wijeyaratne CN, Lazarus JH et al.. “Restricted thyroglobulin antibody epitope specificities in subjects with type 1 diabetes mellitus.” European journal of endocrinology (2009). PMID: 19561043 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors
[73]
Pappa A, Koromantzos P, Seremidi K et al.. “Dental caries and periodontal status in children and adolescents with type 1 diabetes mellitus: an umbrella review.” European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry (2026). PMID: 42270944 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors
[74]
Anesini MB, Pinto M, Bellezza M et al.. “Intentional Insulin Omission (Diabulimia) in Patients with Insulin-Dependent Diabetes: An Eating Disorder? A Systematic Review.” Journal of clinical medicine (2026). PMID: 42123251 ↗
L5SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
[75]
Shao MM, Scheideman AF, Zhou AM et al.. “Accuracy of glutamic acid decarboxylase antibodies for the identification of adult-onset type 1 diabetes mellitus: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 41987896 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[76]
Di Gialleonardo V, de Vries EF, Di Girolamo M et al.. “Imaging of β-cell mass and insulitis in insulin-dependent (Type 1) diabetes mellitus.” Endocrine reviews (2012). PMID: 22889646 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention
[77]
Mackay L, Kilbride L, Adamson KA et al.. “Hormone replacement therapy for women with type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2013). PMID: 23744560 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[78]
Visser J, Snel M, Van Vliet HA. “Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2.” The Cochrane database of systematic reviews (2013). PMID: 23543528 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
[79]
Visser J, Snel M, Van Vliet HA. “Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2.” The Cochrane database of systematic reviews (2006). PMID: 17054193 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
[80]
Callaghan BC, Little AA, Feldman EL et al.. “Enhanced glucose control for preventing and treating diabetic neuropathy.” The Cochrane database of systematic reviews (2012). PMID: 22696371 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention
[81]
Montero N, Webster AC, Royuela A et al.. “Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients.” The Cochrane database of systematic reviews (2014). PMID: 25220222 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Prognosis, Natural History, Special Populations and Prevention
[82]
Ul-Haq I, Alqahtani HS, Shaheen NA et al.. “Incidence and Risk Factors of Diabetic Retinopathy in Patients with Type 1 Diabetes Mellitus: A Retrospective Study in NGHA, Riyadh, Saudi Arabia.” Journal of clinical medicine (2026). PMID: 42194771 ↗
L3COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention
[83]
Singh M, Subramanian A, Wambua S et al.. “Autoimmune diseases and risk of adverse pregnancy outcomes: a population-based cohort study of five million pregnancies in the UK.” BMC medicine (2026). PMID: 42169116 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention
[84]
Gatira DN, Getnet M, Liyew B et al.. “Incidence and predictors of diabetic ketoacidosis among adults with type 1 diabetes in Northwest, Ethiopia, 2023: a retrospective cohort study.” BMC public health (2026). PMID: 41957727 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, History and Evolution of Treatment, Complications and Long-term Sequelae
[85]
Halpern B, Nery M, Pereira MAA. “Case Report of Acquired Generalized Lipodystrophy Associated With Common Variable Immunodeficiency.” The Journal of clinical endocrinology and metabolism (2018). PMID: 29846625 ↗
L4CASE_REPORTCited in: Clinical Presentation
[86]
Aly HH, Fouda EM, Kotby AA et al.. “COVID-19-Related Multisystem Inflammatory Syndrome in Children Presenting With New-Onset Type 1 Diabetes in Severe Ketoacidosis: A Case Series.” Diabetes care (2022). PMID: 35113159 ↗
L4CASE_REPORTCited in: Clinical Presentation, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention
[87]
Dunn A, Lam A, Hidalgo L et al.. “Autoimmune Thyroid Disease in Islet Transplant Recipients Discontinuing Immunosuppression Late After Lymphodepletion.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30398662 ↗
L4OTHERCited in: Clinical Presentation
[88]
Schreiner F, Plamper M, Dueker G et al.. “Infancy-Onset T1DM, Short Stature, and Severe Immunodysregulation in Two Siblings With a Homozygous LRBA Mutation.” The Journal of clinical endocrinology and metabolism (2016). PMID: 26745254 ↗
L4OTHERCited in: Clinical Presentation
[89]
Johnson SR, Carter HE, Leo P et al.. “Cost-effectiveness Analysis of Routine Screening Using Massively Parallel Sequencing for Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Cohort: Reduced Health System Costs and Improved Patient Quality of Life.” Diabetes care (2018). PMID: 30523035 ↗
L2OTHERCited in: Clinical Presentation, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
[90]
Tsai EB, Sherry NA, Palmer JP et al.. “The rise and fall of insulin secretion in type 1 diabetes mellitus.” Diabetologia (2006). PMID: 16404554 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention
[91]
Aparna KV, Darshan M, Kulkarni A et al.. “Emphysematous pyelonephritis in children: Lessons from a case report and systematic review.” Journal of pediatric urology (2026). PMID: 42285016 ↗
L4SR_OBSCited in: Clinical Presentation, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
[92]
Alqahtani YA, Shati AA, Alshaikh AA et al.. “Prevalence and Recovery of Euthyroid Sick Syndrome in Pediatric Diabetic Ketoacidosis: A Retrospective Cohort Study.” Children (Basel, Switzerland) (2026). PMID: 41749652 ↗
L2COHORTCited in: Clinical Presentation, Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[93]
Li X, Zhang X, Dai X et al.. “Proliferative glomerulonephritis with monoclonal immunoglobulin IgG1-κ deposition in a patient with type 1 diabetes: a case report and literature review.” Frontiers in medicine (2026). PMID: 42375207 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[94]
Bai H, Yu J, Wang T et al.. “Case Report: A novel likely pathogenic GCK variant in a young Chinese girl with severe insulin resistance.” Frontiers in endocrinology (2026). PMID: 42137361 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[95]
Liu S, Cao C, Wang X. “Autoimmune polyglandular syndrome type 1 with compound heterozygous AIRE gene pathogenic variants and stage 1 type 1 diabetes mellitus: case report and literature review of Chinese population.” Frontiers in immunology (2026). PMID: 41993177 ↗
L4CASE_REPORTCited in: Clinical Presentation, History and Evolution of Treatment
[96]
Valdivia Camacho OD, Allison T, Wilson LB et al.. “Pediatric Cataracts as a Presenting Sign of Type 1 Diabetes Mellitus.” The Journal of pediatrics (2025). PMID: 40945580 ↗
L4CASE_REPORTCited in: Clinical Presentation
[97]
Maruyama T, Tanaka S, Shimada A et al.. “Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2008). PMID: 18397986 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment
[98]
Matejko B, Juza A, Kieć-Wilk B et al.. “Transitioning of People With Type 1 Diabetes From Multiple Daily Injections and Self-Monitoring of Blood Glucose Directly to MiniMed 780G Advanced Hybrid Closed-Loop System: A Two-Center, Randomized, Controlled Study.” Diabetes care (2022). PMID: 35972259 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[99]
Luijf YM, DeVries JH, Zwinderman K et al.. “Day and night closed-loop control in adults with type 1 diabetes: a comparison of two closed-loop algorithms driving continuous subcutaneous insulin infusion versus patient self-management.” Diabetes care (2013). PMID: 24170747 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[100]
Ma X, Xie Z, Qin J et al.. “Association of Vitamin D Pathway Gene CYP27B1 and CYP2R1 Polymorphisms with Autoimmune Endocrine Disorders: A Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32915988 ↗
L3SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[101]
Ludvigsson J, Faresjö M, Hjorth M et al.. “GAD treatment and insulin secretion in recent-onset type 1 diabetes.” The New England journal of medicine (2008). PMID: 18843118 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[102]
Tamborlane WV, Beck RW, Bode BW et al.. “Continuous glucose monitoring and intensive treatment of type 1 diabetes.” The New England journal of medicine (2008). PMID: 18779236 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[103]
Ludvigsson J, Krisky D, Casas R et al.. “GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.” The New England journal of medicine (2012). PMID: 22296077 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[104]
Zhong VW, Juhaeri J, Mayer-Davis EJ. “Trends in Hospital Admission for Diabetic Ketoacidosis in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study.” Diabetes care (2018). PMID: 29386248 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
[105]
Szypowska A, Ramotowska A, Dzygalo K et al.. “Beneficial effect of real-time continuous glucose monitoring system on glycemic control in type 1 diabetic patients: systematic review and meta-analysis of randomized trials.” European journal of endocrinology (2011). PMID: 22096111 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention
[106]
Teo E, Hassan N, Tam W et al.. “Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis.” Diabetologia (2022). PMID: 35141761 ↗
L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies
[107]
Orban T, Bundy B, Becker DJ et al.. “Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2011). PMID: 21719096 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[108]
Schultz ANØ, Christensen R, Bollig G et al.. “Effectiveness of video consultations in type 1 diabetes patients treated with insulin pumps in the outpatient clinic: a randomised controlled trial.” Diabetologia (2025). PMID: 41198916 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[109]
Benhalima K, van Nes F, Laenen A et al.. “Risk for ketonaemia in type 1 diabetes pregnancies with sensor-augmented pump therapy with predictive low glucose suspend compared with low glucose suspend: a crossover RCT.” Diabetologia (2021). PMID: 34647140 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention
[110]
Gejl M, Gjedde A, Brock B et al.. “Effects of hypoglycaemia on working memory and regional cerebral blood flow in type 1 diabetes: a randomised, crossover trial.” Diabetologia (2017). PMID: 29188338 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment
[111]
Golicki DT, Golicka D, Groele L et al.. “Continuous Glucose Monitoring System in children with type 1 diabetes mellitus: a systematic review and meta-analysis.” Diabetologia (2007). PMID: 18060380 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[112]
Goldacre RR. “Associations between birthweight, gestational age at birth and subsequent type 1 diabetes in children under 12: a retrospective cohort study in England, 1998-2012.” Diabetologia (2017). PMID: 29128935 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[113]
De Meulemeester J, Keymeulen B, De Block C et al.. “One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study.” Diabetologia (2025). PMID: 39934368 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[114]
Yapanis M, James S, Craig ME et al.. “Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35094087 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[115]
Shalimova A, Graff B, Gąsecki D et al.. “Cognitive Dysfunction in Type 1 Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30657922 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Complications and Long-term Sequelae
[116]
Prinz N, Tittel SR, Bachran R et al.. “Characteristics of Patients with Type 1 Diabetes and Additional Autoimmune Disease in the DPV Registry.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34061946 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[117]
Wang Y, Qin Y, Gu H et al.. “High Residual β-cell Function in Chinese Patients With Autoimmune Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35218654 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
[118]
Menon JC, Singh P, Archana A et al.. “High Frequency of Recessive WFS1 Mutations Among Indian Children With Islet Antibody-negative Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37931151 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[119]
Ling P, Yang D, Wang C et al.. “Basal Hyperglycemia Contributes More Than 50% to Time in Range in Pregnant Women With Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38686666 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[120]
Demmer RT, Holtfreter B, Desvarieux M et al.. “The influence of type 1 and type 2 diabetes on periodontal disease progression: prospective results from the Study of Health in Pomerania (SHIP).” Diabetes care (2012). PMID: 22855731 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[121]
Barrett CE, Park J, Kompaniyets L et al.. “Intensive Care Unit Admission, Mechanical Ventilation, and Mortality Among Patients With Type 1 Diabetes Hospitalized for COVID-19 in the U.S.” Diabetes care (2021). PMID: 34158365 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
[122]
Epstein EJ, Osman JL, Cohen HW et al.. “Use of the estimated glucose disposal rate as a measure of insulin resistance in an urban multiethnic population with type 1 diabetes.” Diabetes care (2013). PMID: 23596179 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[123]
Scheuing N, Bartus B, Berger G et al.. “Clinical characteristics and outcome of 467 patients with a clinically recognized eating disorder identified among 52,215 patients with type 1 diabetes: a multicenter german/austrian study.” Diabetes care (2014). PMID: 24623022 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
[124]
van Elderen SG, Brandts A, van der Grond J et al.. “Cerebral perfusion and aortic stiffness are independent predictors of white matter brain atrophy in type 1 diabetic patients assessed with magnetic resonance imaging.” Diabetes care (2011). PMID: 21216862 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[125]
Lundgaard AT, Westergaard D, Röder T et al.. “Longitudinal metabolite and protein trajectories prior to diabetes mellitus diagnosis in Danish blood donors: a nested case-control study.” Diabetologia (2024). PMID: 39078488 ↗
L3CASE_CONTROLCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[126]
Aleksova J, Ebeling PR, Milat F et al.. “DXA-derived advanced hip analysis and the trabecular bone score in end-stage kidney disease secondary to type 1 diabetes.” European journal of endocrinology (2022). PMID: 36315195 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[127]
Martos-Moreno GA, Barrios V, Soriano-Guillén L et al.. “Relationship between adiponectin levels, acylated ghrelin levels, and short-term body mass index changes in children with diabetes mellitus type 1 at diagnosis and after insulin therapy.” European journal of endocrinology (2006). PMID: 17062893 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[128]
Faccinetti NI, Guerra LL, Penas Steinhardt A et al.. “Characterization of zinc transporter 8 (ZnT8) antibodies in autoimmune diabetic patients from Argentinian population using monomeric, homodimeric, and heterodimeric ZnT8 antigen variants.” European journal of endocrinology (2015). PMID: 26567119 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[129]
Rogowicz-Frontczak A, Zozuliłska-Ziołkiewicz D, Litwinowicz M et al.. “Are zinc transporter type 8 antibodies a marker of autoimmune thyroiditis in non-obese adults with new-onset diabetes?” European journal of endocrinology (2014). PMID: 24480135 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention
[130]
Krassas GE, Tziomalos K, Pontikides N et al.. “Seasonality of month of birth of patients with Graves' and Hashimoto's diseases differ from that in the general population.” European journal of endocrinology (2007). PMID: 17535862 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[131]
Lin Q, Zhou Y, Lei M et al.. “Efficacy and safety of automated insulin delivery system in very young children with type 1 diabetes: A systematic review and meta-analysis of randomized controlled trials.” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 42108409 ↗
L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
[132]
Murray JA, Husby S. “Celiac Disease.” The New England journal of medicine (2026). PMID: 41950475 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[133]
Langendam M, Luijf YM, Hooft L et al.. “Continuous glucose monitoring systems for type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2012). PMID: 22258980 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[134]
Clar C, Waugh N, Thomas S. “Routine hospital admission versus out-patient or home care in children at diagnosis of type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2007). PMID: 17443539 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
[135]
Mărgineanu C, Usatiuc LO, Sur ML et al.. “The Bidirectional Relationship Between Type 1 Diabetes Mellitus and Obesity in Pediatric Patients: A Systematic Review.” Children (Basel, Switzerland) (2026). PMID: 42353914 ↗
L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
[136]
Ma IH, Huang WL, Liu YL et al.. “Early Retinal Changes Detected Using Optical Coherence Tomography Angiography in Youth with Type 1 Diabetes Mellitus: A Case-Control Study.” Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde (2026). PMID: 41984745 ↗
L3CASE_CONTROLCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[137]
Harada K, Okazaki Y, Ichiba T. “Prehospital identification of hypoglycemia-induced seizure using a smartphone-linked continuous glucose monitoring application.” The American journal of emergency medicine (2026). PMID: 42119276 ↗
L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[138]
Jiang Y, Cui Y, Su D et al.. “Immune checkpoint inhibitor-associated diabetic ketoacidosis induced by cadonilimab: a case report and literature review.” Frontiers in endocrinology (2026). PMID: 42058780 ↗
L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment
[139]
Wherrett DK, Bundy B, Becker DJ et al.. “Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.” Lancet (London, England) (2011). PMID: 21714999 ↗
L1RCTCited in: Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[140]
Shao W, Yang K, Lu D et al.. “Endocrine Adverse Reactions of Tyrosine Kinase Inhibitors in Combination With Immune Checkpoint Inhibitors.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39986331 ↗
L3OTHERCited in: Severity, Staging and Risk Stratification
[141]
Antonoglou G, Knuuttila M, Niemelä O et al.. “Serum 1,25(OH)D level increases after elimination of periodontal inflammation in T1DM subjects.” The Journal of clinical endocrinology and metabolism (2013). PMID: 23940127 ↗
L2OTHERCited in: Severity, Staging and Risk Stratification
[142]
Mistry S, Gouripeddi R, Raman V et al.. “Stratifying risk for onset of type 1 diabetes using islet autoantibody trajectory clustering.” Diabetologia (2022). PMID: 36446887 ↗
L2OTHERCited in: Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention
[143]
Liu GC, Fang F, Zhou J et al.. “Deletion of p47phox attenuates the progression of diabetic nephropathy and reduces the severity of diabetes in the Akita mouse.” Diabetologia (2012). PMID: 22653270 ↗
L5OTHERCited in: Severity, Staging and Risk Stratification
[144]
Broe R, Rasmussen ML, Frydkjaer-Olsen U et al.. “Retinal vascular fractals predict long-term microvascular complications in type 1 diabetes mellitus: the Danish Cohort of Pediatric Diabetes 1987 (DCPD1987).” Diabetologia (2014). PMID: 24981770 ↗
L2OTHERCited in: Severity, Staging and Risk Stratification
[145]
Yılmaz UC, Kızılay DÖ, Kurt ÖK et al.. “Autoantibody screening in children who are first-degree relatives of individuals with type 1 diabetes in a sibling-dominant cohort in Turkey: a multicentre study on prevalence, determinants and post-screening parent-child anxiety.” Diabetologia (2026). PMID: 42350669 ↗
L4OTHERCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies
[146]
Idrees H, Memon F, Alam R et al.. “Systematic Review and Meta-Analysis of Insulin Dose and Route of Administration Regimens for Diabetic Ketoacidosis in Children and Adolescents.” Journal of clinical medicine (2025). PMID: 41227190 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification
[147]
Fullerton B, Siebenhofer A, Jeitler K et al.. “Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2016). PMID: 27362975 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[148]
Fullerton B, Jeitler K, Seitz M et al.. “Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2014). PMID: 24526393 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies
[149]
Zhang Q, Saad SH, Zhou H et al.. “Development and validation of an interpretable machine learning model for predicting in-hospital hypoglycemia in adults with type 1 diabetes mellitus: a multicenter retrospective study.” Frontiers in endocrinology (2026). PMID: 42095183 ↗
L2COHORTCited in: Severity, Staging and Risk Stratification
[150]
Wang S, Zhang Y, Balati A et al.. “Effect of Sodium-glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 1 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39812177 ↗
L1SR_MA_RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[151]
Cherney DZ, Reich HN, Scholey JW et al.. “The effect of aliskiren on urinary cytokine/chemokine responses to clamped hyperglycaemia in type 1 diabetes.” Diabetologia (2013). PMID: 23893332 ↗
L2TRIAL_NONRANDOMCited in: Acute Management and Endocrine Emergencies
[152]
Marzuillo P, Iafusco D, Zanfardino A et al.. “Acute Kidney Injury and Renal Tubular Damage in Children With Type 1 Diabetes Mellitus Onset.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33595665 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies
[153]
Dugan CW, Maloney SK, Abramoff KJ et al.. “Effects of Simulated High Altitude on Blood Glucose Levels During Exercise in Individuals With Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34935935 ↗
L1OTHERCited in: Acute Management and Endocrine Emergencies
[154]
Owens LA, Avalos G, Kirwan B et al.. “ATLANTIC DIP: closing the loop: a change in clinical practice can improve outcomes for women with pregestational diabetes.” Diabetes care (2012). PMID: 22826448 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies
[155]
Goedendorp MM, Tack CJ, Steggink E et al.. “Chronic fatigue in type 1 diabetes: highly prevalent but not explained by hyperglycemia or glucose variability.” Diabetes care (2013). PMID: 23949561 ↗
L3OTHERCited in: Acute Management and Endocrine Emergencies
[156]
Tsujimoto T, Yamamoto-Honda R, Kajio H et al.. “Vital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in type 1 and type 2 diabetic patients.” Diabetes care (2013). PMID: 23939540 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies
[157]
Chantzichristos D, Eliasson B, Johannsson G. “MANAGEMENT OF ENDOCRINE DISEASE Disease burden and treatment challenges in patients with both Addison's disease and type 1 diabetes mellitus.” European journal of endocrinology (2020). PMID: 32299062 ↗
L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[158]
Barchetta I, Alessandri C, Bertoccini L et al.. “Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile.” European journal of endocrinology (2015). PMID: 26578639 ↗
L3OTHERCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
[159]
Ishida-Oku M, Iwase M, Sugitani A et al.. “A case of recurrent type 1 diabetes mellitus with insulitis of transplanted pancreas in simultaneous pancreas-kidney transplantation from cardiac death donor.” Diabetologia (2009). PMID: 19911164 ↗
L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies
[160]
Assogba FG, Couchoud C, Hannedouche T et al.. “Trends in the epidemiology and care of diabetes mellitus-related end-stage renal disease in France, 2007-2011.” Diabetologia (2014). PMID: 24496924 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
[161]
Beulens JW, Kruidhof JS, Grobbee DE et al.. “Alcohol consumption and risk of microvascular complications in type 1 diabetes patients: the EURODIAB Prospective Complications Study.” Diabetologia (2008). PMID: 18626626 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies
[162]
Gomes JAF, Vasconcelos AR, Nascimento Júnior JRAD et al.. “Perceived Exertion Is Associated with Cardiovascular Strain but Not Glycemic Response to Gym-Based Exercise in Adults with Type 1 Diabetes: An Exploratory Randomized Crossover Trial.” International journal of environmental research and public health (2026). PMID: 42354343 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
[163]
Mitchell S, Patwardhan K, Lucocq J et al.. “Metabolic and bariatric surgery for patients with obesity type 1 diabetes mellitus: A comprehensive updated systematic review and meta-analysis.” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 41904365 ↗
L1SR_OBSCited in: Acute Management and Endocrine Emergencies
[164]
Guo Y, Mei Y, Bongaerts B et al.. “(Ultra-)short-acting insulin analogues for adults with type 1 diabetes mellitus on multiple daily injections: a network meta-analysis.” The Cochrane database of systematic reviews (2026). PMID: 42318853 ↗
L1SR_OBSCited in: Acute Management and Endocrine Emergencies
[165]
Skott E, Cai W, Stiernborg M et al.. “Associations of prenatal exposure to maternal autoimmune disorders with a wide spectrum of psychiatric and neurodevelopmental disorders in offspring-a nationwide cohort study.” Human reproduction open (2026). PMID: 42077501 ↗
L2COHORTCited in: Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention
[166]
Kim JY, Kim S, Kim JH. “Association between Continuous Glucose Monitoring and Risk of Acute Diabetes-Related Complications in Pediatric Type 1 Diabetes Mellitus: A Nationwide Cohort Study.” Diabetes & metabolism journal (2026). PMID: 42014052 ↗
L2COHORTCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
[167]
Kang YM, Giugliano RP, Ran X et al.. “Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial.” Diabetes care (2025). PMID: 40544474 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
[168]
Ruiz de Adana MS, Alhambra-Expósito MR, Muñoz-Garach A et al.. “Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA1c in Andalusia (Spain): PLATEDIAN Study.” Diabetes care (2019). PMID: 31831473 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[169]
Porcellati F, Lucidi P, Candeloro P et al.. “Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes.” Diabetes care (2018). PMID: 30305345 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[170]
Rys PM, Ludwig-Slomczynska AH, Cyganek K et al.. “Continuous subcutaneous insulin infusion vs multiple daily injections in pregnant women with type 1 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials and observational studies.” European journal of endocrinology (2018). PMID: 29545258 ↗
L1SR_MA_RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
[171]
Ocheltree SM, Hompesch M, Wondmagegnehu ET et al.. “Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes.” European journal of endocrinology (2010). PMID: 20508081 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[172]
Del Favero S, Bruttomesso D, Di Palma F et al.. “First use of model predictive control in outpatient wearable artificial pancreas.” Diabetes care (2014). PMID: 24757228 ↗
L4TRIAL_NONRANDOMCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[173]
Park J, Ntelis S, Yunasan E et al.. “Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37561012 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[174]
Bergenstal RM, Tamborlane WV, Ahmann A et al.. “Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes.” The New England journal of medicine (2010). PMID: 20587585 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[175]
Russell SJ, El-Khatib FH, Sinha M et al.. “Outpatient glycemic control with a bionic pancreas in type 1 diabetes.” The New England journal of medicine (2014). PMID: 24931572 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[176]
Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al.. “Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.” The New England journal of medicine (2009). PMID: 19940299 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[177]
Osipova J, Fischer DC, Dangwal S et al.. “Diabetes-associated microRNAs in pediatric patients with type 1 diabetes mellitus: a cross-sectional cohort study.” The Journal of clinical endocrinology and metabolism (2014). PMID: 24937532 ↗
L4COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention
[178]
Heller S, Buse J, Fisher M et al.. “Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.” Lancet (London, England) (2012). PMID: 22521071 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
[179]
Beam CA, MacCallum C, Herold KC et al.. “GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis.” Diabetologia (2016). PMID: 27704166 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[180]
Thorius IH, Husemoen LLN, Nordsborg RB et al.. “Congenital malformations among offspring of women with type 1 diabetes who use insulin pumps: a prospective cohort study.” Diabetologia (2023). PMID: 36640191 ↗
L2COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
[181]
Al-Naseem AO, Attia A, Gonnah AR et al.. “Pancreas transplantation today: quo vadis?” European journal of endocrinology (2023). PMID: 36929837 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
[182]
Wiegand S, Raile K, Reinehr T et al.. “Daily insulin requirement of children and adolescents with type 1 diabetes: effect of age, gender, body mass index and mode of therapy.” European journal of endocrinology (2008). PMID: 18362302 ↗
L2OTHERCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[183]
Moser O, Becker U, van den Boom L et al.. “[Automated insulin delivery (AID) systems, physical activity and sports in type 1 diabetes mellitus: joint guidelines of the DDG and ÖDG].” Wiener klinische Wochenschrift (2026). PMID: 42162485 ↗
L1GUIDELINECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention
[184]
Amaral R, Costa B, Penedones A et al.. “Efficacy and Safety of Once-Weekly and Once-Daily Basal Insulins in Type 1 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis of Clinical Trials.” Diabetes, obesity & metabolism (2026). PMID: 42225295 ↗
L1TRIAL_NONRANDOMCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[185]
Bellin MD, Dunn TB. “Transplant strategies for type 1 diabetes: whole pancreas, islet and porcine beta cell therapies.” Diabetologia (2020). PMID: 32894315 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[186]
Tamahane V, Shah N, Kajale N et al.. “Effect of prebiotic intervention on glycemic control and gut microbiome profile in Indian children with type 1 diabetes mellitus (T1DM): a pilot randomised control trial.” Endocrine (2026). PMID: 42165942 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[187]
Campbell F, Biggs K, Aldiss SK et al.. “Transition of care for adolescents from paediatric services to adult health services.” The Cochrane database of systematic reviews (2016). PMID: 27128768 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[188]
Abdelghaffar S, Attia AM. “Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents.” The Cochrane database of systematic reviews (2009). PMID: 19160294 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[189]
Hemmingsen B, Metzendorf MI, Richter B. “(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2021). PMID: 33662147 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
[190]
Vardi M, Jacobson E, Nini A et al.. “Intermediate acting versus long acting insulin for type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2008). PMID: 18646147 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[191]
Misso ML, Egberts KJ, Page M et al.. “Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2010). PMID: 20091571 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[192]
Copur S, Mizrak B, Ozbek L et al.. “Once-Weekly Subcutaneous Insulin Efsitora for the Management of Diabetes Mellitus: A Systematic Review and Meta-Analysis Study.” Medeniyet medical journal (2026). PMID: 42383405 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[193]
Toghi-Eshghi SR, Yardley JE. “Morning (Fasting) vs Afternoon Resistance Exercise in Individuals With Type 1 Diabetes: A Randomized Crossover Study.” The Journal of clinical endocrinology and metabolism (2019). PMID: 31211392 ↗
L1RCTCited in: History and Evolution of Treatment
[194]
Parthasarathy G, Kudva YC, Low PA et al.. “Relationship Between Gastric Emptying and Diurnal Glycemic Control in Type 1 Diabetes Mellitus: A Randomized Trial.” The Journal of clinical endocrinology and metabolism (2017). PMID: 27880079 ↗
L1RCTCited in: History and Evolution of Treatment
[195]
Haider DG, Pleiner J, Francesconi M et al.. “Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes.” The Journal of clinical endocrinology and metabolism (2006). PMID: 16895956 ↗
L4RCTCited in: History and Evolution of Treatment
[196]
Sarem Z, Bumke-Vogt C, Mahmoud AM et al.. “Glucagon Decreases IGF-1 Bioactivity in Humans, Independently of Insulin, by Modulating Its Binding Proteins.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28911141 ↗
L1RCTCited in: History and Evolution of Treatment
[197]
Crowne EC, Samra JS, Cheetham T et al.. “The role of IGF-binding proteins in mediating the effects of recombinant human IGF-I on insulin requirements in type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2001). PMID: 11502796 ↗
L1RCTCited in: History and Evolution of Treatment
[198]
Griffen SC, Oostema K, Stanhope KL et al.. “Administration of Lispro insulin with meals improves glycemic control, increases circulating leptin, and suppresses ghrelin, compared with regular/NPH insulin in female patients with type 1 diabetes.” The Journal of clinical endocrinology and metabolism (2005). PMID: 16317063 ↗
L1RCTCited in: History and Evolution of Treatment
[199]
Herold KC, Hagopian W, Auger JA et al.. “Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.” The New England journal of medicine (2002). PMID: 12037148 ↗
L1RCTCited in: History and Evolution of Treatment
[200]
. “Effects of insulin in relatives of patients with type 1 diabetes mellitus.” The New England journal of medicine (2002). PMID: 12037147 ↗
L1RCTCited in: History and Evolution of Treatment
[201]
Nathan DM, Lachin J, Cleary P et al.. “Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus.” The New England journal of medicine (2003). PMID: 12788993 ↗
L2RCTCited in: History and Evolution of Treatment
[202]
Keymeulen B, Vandemeulebroucke E, Ziegler AG et al.. “Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.” The New England journal of medicine (2005). PMID: 15972866 ↗
L1RCTCited in: History and Evolution of Treatment
[203]
Skyler JS, Cefalu WT, Kourides IA et al.. “Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study.” Lancet (London, England) (2001). PMID: 11210993 ↗
L1RCTCited in: History and Evolution of Treatment
[204]
Shapiro AM, Lakey JR, Ryan EA et al.. “Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.” The New England journal of medicine (2000). PMID: 10911004 ↗
L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment
[205]
Bally L, Zueger T, Buehler T et al.. “Metabolic and hormonal response to intermittent high-intensity and continuous moderate intensity exercise in individuals with type 1 diabetes: a randomised crossover study.” Diabetologia (2016). PMID: 26739816 ↗
L1RCTCited in: History and Evolution of Treatment
[206]
Ang M, Meyer C, Brendel MD et al.. “Magnitude and mechanisms of glucose counterregulation following islet transplantation in patients with type 1 diabetes suffering from severe hypoglycaemic episodes.” Diabetologia (2013). PMID: 24305963 ↗
L3RCTCited in: History and Evolution of Treatment
[207]
Garg S, Rosenstock J, Silverman BL et al.. “Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes.” Diabetologia (2006). PMID: 16506054 ↗
L1RCTCited in: History and Evolution of Treatment
[208]
Davison GW, Ashton T, George L et al.. “Molecular detection of exercise-induced free radicals following ascorbate prophylaxis in type 1 diabetes mellitus: a randomised controlled trial.” Diabetologia (2008). PMID: 18769906 ↗
L1RCTCited in: History and Evolution of Treatment
[209]
Jenni S, Oetliker C, Allemann S et al.. “Fuel metabolism during exercise in euglycaemia and hyperglycaemia in patients with type 1 diabetes mellitus--a prospective single-blinded randomised crossover trial.” Diabetologia (2008). PMID: 18512043 ↗
L1RCTCited in: History and Evolution of Treatment
[210]
Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S et al.. “Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus.” Lancet (London, England) (2001). PMID: 11418149 ↗
L2TRIAL_NONRANDOMCited in: History and Evolution of Treatment
[211]
Edwards K, Li X, Lingvay I. “Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36268825 ↗
L4OTHERCited in: History and Evolution of Treatment
[212]
Galassetti P, Tate D, Neill RA et al.. “Effect of gender on counterregulatory responses to euglycemic exercise in type 1 diabetes.” The Journal of clinical endocrinology and metabolism (2002). PMID: 12414885 ↗
L4OTHERCited in: History and Evolution of Treatment
[213]
Kudva YC, Reynolds C, O'Brien T et al.. “"Diabetic mastopathy," or sclerosing lymphocytic lobulitis, is strongly associated with type 1 diabetes.” Diabetes care (2002). PMID: 11772912 ↗
L3OTHERCited in: History and Evolution of Treatment
[214]
Lu CL, Shen HN, Hu SC et al.. “A Population-Based Study of All-Cause Mortality and Cardiovascular Disease in Association With Prior History of Hypoglycemia Among Patients With Type 1 Diabetes.” Diabetes care (2016). PMID: 27385329 ↗
L3OTHERCited in: History and Evolution of Treatment, Complications and Long-term Sequelae
[215]
Cabrera SM, Chen YG, Hagopian WA et al.. “Blood-based signatures in type 1 diabetes.” Diabetologia (2015). PMID: 26699650 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention
[216]
Zhang Q, Zhou H, Lin R et al.. “Risk factors for hypoglycaemia in adults with type 1 diabetes: a systematic review and meta-analysis.” BMC endocrine disorders (2025). PMID: 41449374 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[217]
Garabedian C, Sénat MV, Sananès N et al.. “[Preexisting diabetes: Expert consensus from the College of French Gynecologists and Obstetricians and from the French Society of Diabetology].” Gynecologie, obstetrique, fertilite & senologie (2025). PMID: 41365423 ↗
L1GUIDELINECited in: History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[218]
Tang D, Gao X, Zhu M et al.. “Population Pharmacokinetic and Pharmacodynamic Modeling to Support Molar Dose Ratio Determination of Long-Acting Insulin Analogs.” Clinical pharmacokinetics (2026). PMID: 41489799 ↗
L4RCTCited in: History and Evolution of Treatment
[219]
Drai R, Galstyan G, Karonova T et al.. “Immunogenicity, efficacy and safety of a biosimilar insulin glulisine compared with originator in adults with type 1 diabetes mellitus: A phase III randomised clinical trial.” Diabetes, obesity & metabolism (2025). PMID: 41366610 ↗
L1RCTCited in: History and Evolution of Treatment
[220]
Almutairi MNASF. “Neurodevelopmental effects of severe hypoglycemia in children with type 1 diabetes: a systematic review.” Frontiers in pediatrics (2026). PMID: 41660395 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[221]
Aoki TT, Benbarka MM, Okimura MC et al.. “Long-term intermittent intravenous insulin therapy and type 1 diabetes mellitus.” Lancet (London, England) (1993). PMID: 8102666 ↗
L4OTHERCited in: History and Evolution of Treatment
[222]
Kugathasan L, Katz A, Muskiet MHA et al.. “Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus.” Kidney international reports (2026). PMID: 42205183 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[223]
Pham-Dobor G, Kaltenecker P, Temesfoi V et al.. “Systematic Analysis and Network Mapping of Disease Associations in Autoimmune Polyglandular Syndrome.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39378147 ↗
L4OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[224]
Łebkowska A, Adamska A, Krentowska A et al.. “The Influence of Prepubertal Onset of Type 1 Diabetes and Age of Menarche on Polycystic Ovary Syndrome Diagnosis.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33537700 ↗
L4OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[225]
van Dijk M, Donga E, van Dijk JG et al.. “Disturbed subjective sleep characteristics in adult patients with long-standing type 1 diabetes mellitus.” Diabetologia (2011). PMID: 21573904 ↗
L3OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[226]
Xiao YL, Jia YQ, Gu LQ et al.. “Prevalence of Celiac Disease in China Among High-Risk Populations: A Systematic Review and Meta-Analysis.” Journal of digestive diseases (2025). PMID: 41183986 ↗
L1SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[227]
Fagerholm E, Ahlqvist E, Forsblom C et al.. “SNP in the genome-wide association study hotspot on chromosome 9p21 confers susceptibility to diabetic nephropathy in type 1 diabetes.” Diabetologia (2012). PMID: 22643932 ↗
L3SR_OBSCited in: Complications and Long-term Sequelae
[228]
González-Clemente JM, Vilardell C, Broch M et al.. “Lower heart rate variability is associated with higher plasma concentrations of IL-6 in type 1 diabetes.” European journal of endocrinology (2007). PMID: 17609399 ↗
L4OTHERCited in: Complications and Long-term Sequelae
[229]
Głowińska-Olszewska B, Moniuszko M, Hryniewicz A et al.. “Relationship between circulating endothelial progenitor cells and endothelial dysfunction in children with type 1 diabetes: a novel paradigm of early atherosclerosis in high-risk young patients.” European journal of endocrinology (2013). PMID: 23111589 ↗
L3OTHERCited in: Complications and Long-term Sequelae
[230]
Nathan DM. “Realising the long-term promise of insulin therapy: the DCCT/EDIC study.” Diabetologia (2021). PMID: 33550441 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae
[231]
Chimen M, Kennedy A, Nirantharakumar K et al.. “What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review.” Diabetologia (2011). PMID: 22189486 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae
[232]
Colombo M, McGurnaghan SJ, Bell S et al.. “Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus.” Diabetologia (2019). PMID: 31807796 ↗
L2OTHERCited in: Complications and Long-term Sequelae
[233]
Cakmak Demir S, Batman A, Yazici D et al.. “Association of High-Risk Obstructive Sleep Apnea with Microvascular Complications in Adults with Type 1 Diabetes Mellitus: A Case-Control Study.” Journal of clinical medicine (2026). PMID: 42074704 ↗
L3CASE_CONTROLCited in: Complications and Long-term Sequelae
[234]
Rodrigues F, White M, O'Connell MA. “Hyperlipidaemia in youth with type 1 diabetes: Are current guidelines clinically useful?” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 42387672 ↗
L4OTHERCited in: Complications and Long-term Sequelae
[235]
Tentolouris A, Popovic DS, Liarakos AL et al.. “GLP-1-Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes.” Diabetes, obesity & metabolism (2026). PMID: 42380553 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae
[236]
García-Poblet M, Martínez-Sanz JM, Alberola-Chazarra MA et al.. “Phase angle and triglyceride-glucose index as biomarkers of glycemic control, body composition and cardiovascular risk in adolescents with type 1 diabetes: a cross-sectional study.” Journal of endocrinological investigation (2026). PMID: 42371339 ↗
L4OTHERCited in: Complications and Long-term Sequelae
[237]
Buschur EO, Polsky S. “Type 1 Diabetes: Management in Women From Preconception to Postpartum.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33331893 ↗
L5SR_OBSCited in: Prognosis, Natural History, Special Populations and Prevention
[238]
Basu A, Alaupovic P, Wu M et al.. “Plasma lipoproteins and preeclampsia in women with type 1 diabetes: a prospective study.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22438226 ↗
L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention
[239]
Kim KM, Kim KJ, Han K et al.. “Associations Between Physical Activity and the Risk of Hip Fracture Depending on Glycemic Status: A Nationwide Cohort Study.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37850407 ↗
L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention
[240]
Castellaneta S, Piccinno E, Oliva M et al.. “High rate of spontaneous normalization of celiac serology in a cohort of 446 children with type 1 diabetes: a prospective study.” Diabetes care (2015). PMID: 25784659 ↗
L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention
[241]
Allen LA, Cannings-John RL, Evans A et al.. “Pregnancy in teenagers diagnosed with type 1 diabetes mellitus in childhood: a national population-based e-cohort study.” Diabetologia (2019). PMID: 31863141 ↗
L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention
[242]
Tosur M, Geyer SM, Rodriguez H et al.. “Ethnic differences in progression of islet autoimmunity and type 1 diabetes in relatives at risk.” Diabetologia (2018). PMID: 29931415 ↗
L2OTHERCited in: Prognosis, Natural History, Special Populations and Prevention
[243]
García-Patterson A, Gich I, Amini SB et al.. “Insulin requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of direction.” Diabetologia (2009). PMID: 20013109 ↗
L4OTHERCited in: Prognosis, Natural History, Special Populations and Prevention